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ABSTRACT
The

dopamine

transporter

(DAT)

is

a

neuronal

presynaptic

transmembrane protein that clears released dopamine (DA) from the synaptic
space, regulating the neurotransmitter concentration and availability. DAT and
the related serotonin (SERT) and norepinephrine (NET) transporters belong to
the SLC 6 family of Na+ and Cl' dependent symporters, and are major targets for
the action of several drugs, including the psychostimulant cocaine. DAT is
predicted to possess 12 transmembrane spanning domains (TMs), with both Nand C-termini located intracellulariy. Extensive research efforts to gain insight on
the molecular aspects of DAT have been attempted, but the three-dimensional
arrangement of the protein as well as the molecular mechanisms involved in
substrate translocation remain undiscovered.
Cocaine and other structurally diverse compounds bind to DAT with high
affinity and inhibit its transport activity, but their binding site within the protein and
the mechanism by which they block DA transport remain unclear. Two distinct
ligand interaction sites at transmembrane domains (TMs) 1-2 and 4-6 have been
identified using irreversible uptake-blockers. The current studies explore the
incorporation site of the novel cocaine analogue [125l]MFZ-2-24, which is
structurally similar to the previously characterized [ 125I]RTI 82, but the reactive
azido (Ns) group is differentially positioned within the cocaine pharmacophore.
Trypsin and cyanogen bromide (CNBr) proteolytic maps of [125!]MFZ-2-24
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labeled rat and human DATs, followed by epitope-specific immunoprecipitation
were used to localize the incorporation site of the ligand to a 13 amino acid
stretch in Tl

, between residues I67 and L80. This highly conserved region

harbors the functionally essential D79 and residues involved in substrate and
inhibitor binding. In marked contrast, incorporation of [ 125I]RTI 82 occurs in TM 6 ,
demonstrating that differential positioning of the N3 group on the cocaine
pharmacophore leads to distinct incorporation patterns. This further indicates that
TMs 1 and 6 are in close proximity three-dimensionally and participate in the
reversible binding of cocaine to DAT.

CHAPTER I
INTRODUCTION
The Discovery of Chemical Neurotransmission
Until the end of the 19th century the nerve impulse was believed to
propagate in an electrical manner, but this concept was not proven to be
responsible for the transference of information between nerves and their target
cells. The idea of chemical transmission was initially proposed through studies
involving the physiological effects of adrenal extracts on a variety of tissues. In
1904 Elliott reported the actions of adrenaline in sympathetic axons and
hypothesized that sympathetic nerves communicate chemically with their target
cells, which contain specific recognition sites for these substances [ 1 , reviewed in
2], Between 1920 and 1940 the laboratory of Otto Loewi in Austria studied frog
hearts and proposed that vagal stimulation is due to the actions of acetylcholine
and sympathetic stimulation is mediated by adrenaline [reviewed in 2]. However,
there were many excitatory effects that could not be explained through the
adrenaline hypothesis, especially in tissue of mammalian origin, and in 1946 Ulf
von Euler in Sweden was able to demonstrate that noradrenaline was indeed a
neurotransmitter, and further that it was the main transmitter mediating
mammalian sympathetic nerve communication [reviewed in 2 ].
Since then a plethora of information has become available regarding the
understanding of chemical neurotransmission and its regulation, and many
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chemically diverse compounds have been identified as neurotransmitters in a
variety of nerve terminals across the peripheral and central nervous systems.
Neurotransmitter molecules are synthesized in the body of the neuron and
transported through the axon toward the nerve terminal, where they are actively
packed into storage vesicles that assemble and dock in the active zone. Upon
nerve stimulation neurotransmitters are secreted into the synaptic space via
calcium (Ca2+)-mediated exocytosis. The released transmitters bind to their postsynaptic receptors and activate them, generating downstream effects that lead to
propagation of the action potential. Termination of the signaling events is
accomplished by neurotransmitter enzymatic degradation or reuptake through
membrane transport proteins. Once inside the cell, transmitters are either
repackaged into synaptic vesicles or degraded by intracellular enzymes (Figure
1).
The Characterization of Dopamine as a Central Neurotransmitter
Dopamine
discovered

(3,4-dihydroxyphenylethylamine;

catecholaminergic transmitter in the

DA)

is the

mammalian

most newly
brain.

It is

synthesized from the essential amino acid tyrosine through a two-step enzymatic
reaction that involves the actions of tyrosine hydroxylase (TH) and L-aromatic
amino acid decarboxylase (AADC) (Figure 2).
Until the mid 1950s DA was solely considered a biosynthetic intermediate
of norepinephrine and epinephrine, widely known sympathetic neurotransmitters.
It was then when Carlsson and coworkers demonstrated the normal occurrence
of DA in the brain and suggested that DA was itself a neurotransmitter. These

2

Figure 1. Schematic Diagram of a Dopaminergic Synapse. Newly synthesized
neurotransmitter molecules (DA, blue dots) are actively packed into synaptic
vesicles by the vesicular monoamine transporter 2 (VMAT-2, red cylinders).
Upon arrival of an action potential DA is released via Ca2+'mediated exocytosis
and binds to pre-synaptic (magenta cylinder) and post-synaptic (light blue
cylinders) receptors, resulting in modulation of the pre-synaptic neuron and
propagation of the action potential (green signals), respectively. Termination of
the dopaminergic signal is achieved through Na+/Cr-coupled DA uptake via the
action of the dopamine transporter (DAT) (purple trapezoids). Once inside the
ceil DA is either repackaged into synaptic vesicles or degraded by the
mitochondrial monoamine oxidase (MAO) (orange oval).

3

4

Figure 2. Dopamine Biosynthesis and Degradation Pathway. Biosynthetic
enzymes are labeled in red and catabolic enzymes are labeled in purple. The
conversion of Tyrosine to DOPA via Tyrosine Hydroxylase (TH) is the ratelimiting step in the synthesis of DA.
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researchers observed depletion of catecholamine stores in rabbit’s adrenal
gland, heart and brain upon treatment with the antipsychotic reserpine and
hypothesized that replenishment of the catecholamine stores would revert the
drug’s effects. After administration of the precursor 3,4-dihydroxyphenylalanine
(L-DOPA) they found anti-reserpine effects in treated animals and central
stimulation

in untreated

animals

[3, 4,

reviewed

in 5]. These findings

corresponded with the accumulation of DA, but not norepinephrine in the brains
of these animals, which was, in turn, consistent with DA being a neurotransmitter
on its own. It was not long until the unique distribution of DA was mapped to the
basal ganglia [6], and the development of fluorescent techniques in combination
with pharmacological methods allowed scientists to describe the localization and
distribution of the monoaminergic pathways in the central nervous system (CNS)
[7-11].
Dopaminergic Pathways in the Mammalian Central Nervous System
Dopamine is estimated to account for about 80% of the total brain
catecholamine

content.

However,

the

human

brain

has

relatively

few

dopaminergic neurons, about 150,000-200,000 in each hemisphere, mainly
localized in the midbrain and forebrain. Ultrashort DA systems are comprised by
retina and olfactory bulb neurons, and intermediate-length systems include the
Tuberoinfundibular pathway with DA cells that project from the mesobasal
hypothalamus to the anterior pituitary gland (Figure 3) [12].
The

long

DA

systems

have

been

the

most extensively

studied

dopaminergic neurons and are equally divided between the substantia nigra (SN)

7

Figure 3. Dopaminergic Pathways in the Human Brain. DA neurons from the
substantia nigra project their axons to the striatum, giving rise to the Nigrostriatal
pathway. DA neurons from the ventral tegmental area extend projections to the
mesial components of the limbic system, and to the frontal and prefrontal cortices
to form the Mesolimbic and Mesocortical pathways. The Tuberoinfundibular
pathway contains DA neurons that extend from the mesobasal hypothalamus to
the anterior pituitary gland. The physiological functions associated with each of
these pathways are indicated in bold letters.
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and the ventral tegmental area (VTA) in the basal ganglia. Neurons from the SN
project their axons into the striatum giving rise to the Nigrostriatal pathway, and
neurons from the VTA extend to the mesial components of the limbic system
(nucleus accumbens, amygdala, mesial frontal cortex) and to the frontal and
prefrontal cortices to originate the Mesolimbic and Mesocortica! pathways (Figure
3) [12].
The dopaminergic pathways have a key physiological role in a variety of
processes that include voluntary movement and motor control (Nigrostriatal
pathway), pleasure and reward (Mesolimbic pathway), motivation and attention
(Mesocortical Pathway), and prolactin secretion (Tuberoinr'undibular pathway)
(Figure 3). Malfunctions or dysregulation in these systems have been implicated
in several neuropsychiatric and behavioral disorders, including Parkinson’s
disease (PD), Attention Deficit Hyperactivity Disorder (ADHD), depression,
schizophrenia, and drug abuse.
Dopamine Uptake, Cloning and Localization of the Dopamine Transporter
Termination of acetylcholine signaling was known to be due to enzymatic
degradation via acetylcholinesterase, but it soon became evident that the
mechanisms for catecholamine inactivation were distinctively different. Axelrod
and coworkers discovered that the sympathetic inactivation of norepinephrine
(NE) was caused by its uptake and accumulation back into the nerve terminal
[13], and further that these processes were inhibited by the psychoactive
compounds reserpine, amphetamine (AMPH), imipramine and cocaine [13, 14],
Subsequent characterization revealed that NE uptake followed Michaelis Menten
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saturation kinetics, was stereospecific for the L-isomer, required sodium (Na+),
and was temperature dependent, suggesting that an active transport membrane
carrier system was accountable for this mechanism [15, reviewed in 16 and 17].
In addition, distinctive uptake and pharmacological properties for NE and
DA were observed in brain regions where these transmitters are commonly
found. Although cocaine and AMPH exhibited similar inhibition patterns for both
transmitters, desipramine differentially affected the NE uptake mechanism in the
cortex in contrast with its minor effects on the striatal dopaminergic uptake
system [18]. These observations were extended to synaptosomal preparations of
different brain regions [19], which reinforced the hypothesis that the sites for NE
and DA uptake are different in noradrenergic- and dopaminergic-specific
neurons. The use of a variety of psychostimulants allowed further differentiation
of the catecholaminergic uptake systems in the CNS and the identification of the
DA-specific uptake site in mouse, rat and human striatal tissue [20-22].
The first indication of an association between DA uptake sites and cocaine
was originated by Kennedy and Hanbauer [23], They observed a Na+-dependent
increase in saturable cocaine binding to rat striatal membranes without a change
in affinity, and a strong correlation between the capability of a variety of drugs to
inhibit DA uptake and prevent cocaine binding [23, reviewed in 24], Subsequently
Ritz and coworkers proposed that the cocaine receptor related to substance
abuse was the site linked to inhibition of DA uptake [25], They reported that
cocaine and cocaine analogues triggered self-administration in non-human
primates, and that these substances were potent inhibitors of binding at the
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transport sites for DA [25, reviewed in 24], Although the inhibitory effects of
cocaine were shown at nerve terminals for DA, serotonin (5-HT) and NE, this
group of researchers demonstrated that the inhibition of DA transport was the
principal mechanism involved with cocaine reinforcing effects. Furthermore, their
study indicated a non-significant association between cocaine reinforcement and
either 5-HT or NE inhibition of transport [25].
With these studies it became even clearer that dopamine transporters
were an essential component of the functional dopaminergic synapse and further
that they were pharmacologically important as they were affected by a variety of
substances. In addition, these discoveries sparked deep interest to unveil the

identity of these proteins and, using the sequence for the y-aminobutyric acid
(GABA) transporter (GAT) as a probe, four groups of investigators successfully
cloned the dopamine transporter (DAT) from rat (rDAT) and bovine (bDAT) origin
[26-29]. Soon after and using the rDAT sequence as a template, the human
isoform was cloned [30], followed by the mouse and monkey variants [31,32],
and non-mammalian DATs were identified in the genome of Caenorhabditis
elegance [33], Drosophila melanogaster [34], Eloria noyesi and Bombix mori [35],
In the human brain, DAT is exclusively targeted to dopaminergic neurons,
with the highest expression levels comprised to midbrain neurons that arise in
the SN and VTA. Other regions such as the cortex, amygdala, hypothalamus and
habenula express lower protein levels. At the subcellular level, DAT localizes to
the plasma membrane of neuronal perikarya, dendrites, axons, synaptic
terminals and may also be found in tubulovesicular intracellular structures [36-
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38], A deeper analysis of DAT localization within the synaptic terminals revealed
that the protein is distant from the synaptic area of the presynaptic membrane,
suggesting that clearance of DA happens away from its release site [37], Outside
the CNS, DAT has been found in several other systems, including stomach,
pancreas, kidney and lymphocytes [39,40],
Structural Properties of the Dopamine Transporter
DAT belongs to the SLC6 family of Na+/CI' dependent neurotransmitter
transporters, also known as neurotransmitter:sodium symporters (NSSs), which
are secondary active transporters that mediate solute translocation via coupling
of Na+ and Cl* movement down their electrochemical gradients to upward
movement of substrate. Other members of this family include the related
norepinephrine (NET) and serotonin (SERT) transporters as well as carriers for
GABA, glycine, proline, taurine, betaine, and creatine [reviewed in 41 and 42],
The rDAT and hDAT sequences are the most studied and contain 619 and
620 residues, respectively. Hydropathy profiling predicts 12 transmembrane
spanning domains (TMs), mainly composed of a-helical structure, connected by
extracellular and intracellular loops (ELs and ILs), and the amino- and carboxyterminal tails located intracellularly (Figure 4). Alignment of the mammalian
DATs’ sequences revealed significant homology among them, with the TMs
displaying the highest degree of conservation, and the loops and tails the lowest.
The segment connecting TM3 and TM4, EL2, is the largest loop and represents a
unique feature found within the SLC6 family.
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Figure 4. Schematic Diagram of the Human DAT (hDAT) Primary Sequence. This
shows the extracellular side of the protein at the top and the predicted
transmembrane helices as cylinders. Cysteines 180 and 189 are shown forming
a disulfide bond, and the A/-glycosylated sites are indicated as branched
structures.
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Post-translational Modifications
The presence of a variety of post-translational modifications in DAT
suggests its function is highly regulated. These modifications are located in
regions unique to eukaryotic NSSs, particularly EL2 and the N-terminal tail,
and may thus imply the importance of these domains in regulation of their
properties, perhaps absent in their prokaryotic counterparts.
Sequence analysis revealed the presence of 3 and 4 potential Nglycosylation sites (N-X-S/T) in EL2 of hDAT and rDAT respectively (Figure 4).
AMinked glycosylation at N181, N188, and N205 in hDAT has been associated
with proper cell-surface expression, and changes in transport kinetics and in the
potency of cocaine analogues [43,44]. Two strictly conserved cysteines in DAT
are found in EL2 (C180 and C189) and have been demonstrated to be disulfide
bonded and to participate in the appropriate folding of the protein [45,46] (Figure
4).
The finding of several consensus sites for phophorylation by protein
kinases in the primary sequence of DAT sparked interest for the role of this
modification in transporter function [reviewed in 47,48 and 49]. DAT has been
demonstrated to become phosphorylated in vivo both in constitutive and
stimulated manners in a cluster of serine residues located in the N-terminal tail
[50,51]. This modification has been related to mechanisms involving protein
trafficking, substrate efflux, and protein-protein interactions in DAT, but many
other mechanistical and regulatory aspects of its function remain unclear
[reviewed in 49], In addition, DAT undergoes constitutive and stimulated
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modification by single and short-chain ubiquitin complexes on lysines 19, 27 and
35, located in the N-terminal tail [52], Constitutive ubiquitylation occurs through
the ubiquitin ligase Parkin, whose mutations lead to deficient removal of
abnormal DATs and have been associated with PD [53,*4]. Stimulated
ubiquitylation through the ubiquitin ligase Nedd4-2 triggers movement of DATs
from the plasma membrane into early and then late endosomes, suggesting
degradation via the lysosomal pathway [55,56]
Oligomerization
The presence of oligomeric DAT complexes was initially suggested by in
situ radiation inactivation studies [57], Soon after, chemical cross-linking studies
provided direct evidence for the existence of DAT homodimers via the TM6
residue C306 located within a conserved oligomerization motif (GVXXGVXX). In
addition, the TM4 residue C243 was found to be part of a symmetrical interface
that resulted in tetramers composed of dimers of dimers [58,59].
The use of co-immunoprecipitation and dominant-negative

mutants

revealed the presence of non-covalent high molecular weight DAT complexes,
necessary

for

proper

cell

surface

expression

[43].

Additionally,

DAT

oligomerization between wild-type proteins was demonstrated in living cells using
fluorescence resonance energy transfer (FRET) analysis. The loss of FRET
signals upon coexpression of wild-type and endoplasmic reticulum exportdeficient mutants provided supplementary evidence for the importance of
oligomer formation in the proper assembly and targeting of DATs to the plasma
membrane [60],
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Protein-Protein Interactions
A number of studies using yeast two-hybrid, co-immunoprecipitation,
FRET analysis and mass spectroscopy revealed that DATs interact with various
proteins, mainly via the N- and C-termini [reviewed in 61]. At the N-terminus,
DAT interacts with protein kinase C (PKC) isoforms

and (on, the catalytic

subunit of protein phosphatase 2A (PP2AC), RACK1 (receptor associated with Ckinase) and syntaxin 1A. Interaction partners at the C-terminus include the PDZ
protein PICK1 (protein interacting with C kinase-1), Hic-5, a-synuclein, and
CaMKII (calcium-dependent calmodulin kinase-ll). The identification of this wide
variety of DAT interacting proteins implies that the transporter is present in the
membrane as a complex, rather than as an isolated entity. Furthermore, these
protein-protein interactions have been associated with the regulation of several
aspects of DAT function, including trafficking and transport. The mechanisms by
which these interactions are integrated and regulated remain unclear and its
elucidation will provide a better understanding of DAT function in normal and
pathological states [61].
Functional Properties of DAT
It is well known that the mechanism by which uptake of DA takes place at
the DAT requires concomitant binding and co-transport of Na+ and Cl' ions, with
stoichiometry of 1DA:2Na+:1CI' and energy from the plasma membrane Na+/K+
ATPase. During the translocation process, DAT is proposed to go through a
series of conformational movements that result in alternating exposure of the
central binding site to both the extracellular and intracellular sides of the
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Figure 5. Alternating Access Mechanism for Substrate Translocation. Resting
DATs are open to the extracellular medium in an “outward” conformation. Upon
binding of Na+ (red circles), Cl' (yellow circles) and DA (blue circles) the
transporter undergoes a series of conformational changes that result in an
“inward" facing conformation, where DATs are closed to the extracellular medium
and open to the intracellular side of the membrane. After DA and ions are
released to the intracellular medium DATs reset to the “outward” conformation
and are ready for a new transport cycle.
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membrane. In this “molecular gating” mechanism, DAT is maintained in a
conformation “open” to the extracellular side and “closed” to the intracellular side
of the membrane, where DA and ions bind. Binding triggers a conformational
change and DAT is now “closed" to the extracellular side and “open” to the
intraceilular side of the membrane, where DA and ions are released. The
transporter then resets to the “open” outwardly setting and is ready for a new
transport cycle (Figure 5) [62,63]. Under the influence of amphetamine (AMPH),
DAT promotes release of DA from the cytosol to the extracellular environment via
reverse transport [reviewed in 64]. Additionally, DATs exhibit non-coupled ion
conductances attributed to non-stoichiometric ion movements across the
membrane, analogous to ion channels. These channel-like properties of the
substrate translocation process manifest the presence of “leaking” mechanisms,
demonstrate that the permeation pathway is not perfectly sealed, and are
associated with AMPH-induced efflux [65-68].
Prokaryotic Leucine Transporter and Relationship to DAT
Although many structural and functional characteristics of DAT have been
elucidated since it was cloned in the eariy 1990s, there is currently limited
understanding

regarding

its three dimensional orientation in the

plasma

membrane, the binding sites for DA, ions and uptake blockers, the way the TMs
rearrange during substrate translocation, and the mechanisms that drive
blockade of transport by inhibitors. The lack of understanding of the above
mentioned structural aspects could be attributed mainly to the difficulty in

21

isolating and obtaining a crystal structure from eukaryotic members of the SLC6
family.
A significant advance in this field was provided by studies in the laboratory
of Eric Gouaux, who reported the high-resolution crystal structure of a bacterial
homologue of the NSSs [69]. LeuTAa is a Na+-dependent leucine transporter
isolated from Aquifex aeolicus that shares 20-24% identity with its eukaryotic
counterparts DAT (20%), SERT (21%) and NET (24%). The LeuTAa crystal
structure reveals a pseudo two-fold axis arrangement that associates TMs 1-5
and TMs 6-10, where the leucine and Na+ binding sites are located in a pocket
comprised of TMs 1, 3, 6 and 8. Interestingly, TMs 1 and 6 are juxtaposed and
oriented antiparallel. These domains possess the highest amount of conserved
residues and are not continuous helices. Instead, halfway across the membrane,
the helices display an extended, non-helical conformation that links the two
halves of each domain and allows the exposure of main chain atoms for
coordination of Na+ and leucine binding. The long TMs 3 and 8 also arrange in a
pseudo two-fold axis, exhibiting a -50° angle with respect to the membrane, and
possess highly conserved residues that are positioned near the unwound
portions of TMs 1 and 6. The rest of the TMs surround this central core, and
function as support structures for the correct positioning of the helices in the
active site and as the main contau structures with the lipid bilayer. The Na+ and
leucine binding sites are located contiguously toward the middle portion of the
protein core. In the LeuT/va crystallized conformation, these sites are obstructed
from the aqueous environment by both the extracellular and intracellular gates,
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providing evidence that the protein undergoes three possible conformations
during transport: open to the extracellular medium, closed at both sides, and
open to the intracellular environment. In addition, LeuTAa was crystallized as a
dimer whose interface is composed of EL2, and TMs 9 and 12. Despite evidence
that the eukaryotic NSSs form high-order oligomers, the natural occurrence of
the LeuTAa dimers or the extent of their functional implications remains unclear.
Despite the low overall sequence similarity of LeuTAa with the mammalian
transporters of the SLC6 family, the high conservation found within TMs,
especially those comprising the substrate binding site (TMs 1, 3, 6 and 8), has
already proved that this structure could be used as a framework for molecular
modeling and analysis of NSSs active sites [70-72]. The major differences are
found within the loops and cytoplasmic tails, more specifically the much smaller
EL2 in LeuTAa and the absence of N- and C-terminal tails, which harbor posttranslational

modifications and

protein-protein

interaction domains

in the

mammalian counterparts. The divergences observed in these regions highlight
their importance in the regulation of ion/substrate ratios and transport function,
and further the non-conserved residues in the binding pocket are thought to be
important determinants of substrate specificity for each of the NSSs [71].
Pharmacological Aspects of the Dopamine Transporter
The synthesis, storage, release, reuptake, recycling and metabolism of DA
tightly control the homeostasis of the dopaminergic system. DAT plays a major
regulatory role by modulating the amount of DA in the synaptic cleft, thereby
controlling the intensity and duration of the nerve impulse. When the activity of
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the transporter is disturbed, such as in the presence of cocaine and AMPH, the
levels of DA in the extracellular space are increased. As a consequence, postsynaptic neurons become stimulated to supraphysiological levels, resulting in
euphoria

and

psychomotor

stimulation,

and

ultimately

in

behavioral

reinforcement. This gives rise to what is known as the “dopamine hypothesis of
reinforcement” (Figure 6) [73].
Inhibitors
Cocaine is a psychostimulant drug with euphorigenic and reinforcing
properties, which are believed to be critical determinants for its abuse and
dependence. It is the fifth most widely abused stimulant in western countries and
possesses characteristics common to other addictive substances, such as
tolerance to some of its effects and psychological withdrawal syndrome. Cocaine
is a naturally occurring alkaloid in the leaves of Erythroxylon coca, a plant
endemic in South America, and has been the topic of extensive scientific
investigation since the beginning of the 20th century. Its physiological effects
include local anesthesia and sympathetic as well as psychomotor stimulation,
which provide this agent with an exceptional potential for abuse [reviewed in 74],
Today it is classified as a Schedule II drug, meaning that it has high potential for
abuse, but can be administered by a physician for legitimate medical uses, such
as local anesthesia for some surgeries [75]. Cocaine has been demonstrated to
act as an uptake inhibitor of NE, serotonin (5-HT) and DA via binding to their
cognate transporters, and to have effects on cholinergic, muscarinic and sigma
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Figure 6. The Dopamine Hypothesis of Reinforcement. The normal functioning
dopaminergic system (left panel) is disturbed by the presence of cocaine (®)
(right panel), which binds to DAT (purple trapezoids) and inhibits its transport
activity. As a result, there is an increase in DA concentration at the synaptic cleft
(blue dots) with stimulation of the pre- and post-synaptic receptors (magenta and
light blue cylinders) to supraphysiological levels (green signals).
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receptors [reviewed in 74,76]. However, its reinforcing properties have been
specifically related to its inhibitory actions at DAT (Figure 6).
Other substances that function as DAT uptake inhibitors and join cocaine
in this group include the therapeutic agents GBR 12909 (originally developed to
treat

cocaine

addiction),

bupropion

(Wellbutrin®,

an

antidepressant),

methylphenidate (Ritalin®, therapy for ADHD), and mazindol (Mazindor®, an
appetite suppressant) (Figure 7).
Substrates
Amphetamines (AMPH and methamphetamine-METH) are also powerful CNS
psychostimulants. They were first synthesized at the end of the 19th century from
the alkaloid ephedrine, the active principle from the leaves of Ephedra species.
The physiological effects of AMPH and METH include euphoria, psychomotor
stimulation, decrease in appetite, and general sense of well-being. The main
difference between these substances resides in the fact that, at comparable
doses, METH reaches the CNS much faster and has longer-lasting effects than
AMPH, having greater potential for abuse. AMPH (Aderall®) is currently used as
a standard therapeutic agent for ADHD and narcolepsy, but METH is classified
as a Schedule II drug due to its high abuse potential [77,78]. In contrast to
cocaine and because of their chemical resemblance to dopamine (Figure 7),
amphetamines act as competitive substrates for DAT and become transported
into the presynaptic neuron. The end result is similar to that of cocaine with
respect to increased availability of DA at the synapse. In addition, these
substances cause redistribution of vesicular DA into the cytoplasm, and
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Figure 7. Dopamine Transporter Substrates and Inhibitors. Chemical structures
of A.

the

physiological

substrate

dopamine,

and

the

psychostimulants

amphetamine and methamphetamine that act as substrates at DAT; B. the
neurotoxins 6-hydroxydopamine and 1-methyl-4-phenylpyridinium, which are also
transported by DAT and cause intracellular oxidative damage; C. the uptake
inhibitors cocaine, GBR 12909 and methylphenidate (Ritalin®) that bind to DAT
and block its transport activity.
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reverse transport of DA by DAT, inducing a tremendous spill of DA into the
synaptic space [79, reviewed in 64 and 77],
Neurotoxins
DAT has also been demonstrated to be the gateway for several
neurotoxins that act as substrates and become transported into the cytoplasm
due to their structural resemblance to DA. 1-methyi-4-phenylpyridinium (MPP+) is
the oxidation product of the widely characterized neurotoxin 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) (Figure 7). MPP+ enters the neuron through
DAT and triggers harmful intracellular events that include oxidative stress and
disruption of mitochondrial respiration, ultimately leading to selective neuronal
deterioration and Parkinson-like syndrome in mammals [80,81]. The naturally
occurring toxin 6-hydroxydopamine (6-OHDA) is produced by non-enzymatic
hydroxylation of DA and is widely used to obtain animal models of PD. Once
inside the cell it causes oxidative stress via production of reactive oxygen
species (ROS), leading to cellular, mitochondrial and DNA damage [80,81].
The toxic actions of these substances in dopaminergic neurons and the
fact that they cause their detrimental effects by entering the cell through DAT
suggest a potentially important role of this protein in the selective degeneration of
DA neurons characteristic of PD. Despite the presence of evidence suggesting
an environmental component in the etiology of idiopathic PD, researchers have
yet to find a specific toxin in the brains of these patients and the DAT hypothesis
appears to be one of several factors contributing to the cascade of events that
leads to the pathogenesis of PD [80].
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Lessons from DAT Knockout Mice
The role of the dopaminergic system in association with the molecular
events that lead to drug abuse, and specifically the involvement of DAT in
maintaining neuronal homeostasis has been strengthened and extended by
studies in knockout animals. In 1996, Caron and coworkers reported the
production and analysis of a DAT knockout mouse (DAT7') that exhibits unique
neurochemical and behavioral characteristics [82]. The biochemistry of the
nigrostriatal DA system is profoundly altered in these animals, with elevated
extracellular DA levels, disrupted DA removal, decreased levels of intracellular
DA and TH, and down-regulation of pre- and post-synaptic DA receptors. In
these animals, DA persists in the extracellular space at least 100 times longer
than in the presence of DAT because diffusion is the only remaining mechanism
for DA clearance. DA knockout mice display highly elevated spontaneous
locomotion (5-6 times more active), reduced size, cognitive deficiencies, and
sleep impairment [reviewed in 83, 84]. Injections of high doses of cocaine and
AMPH in the striatal tissue produced no significant increases in locomotor
effects. In addition, methylphenidate and MPTP also fail to affect DA-related
processes in these animals [reviewed in 83]. Interestingly, despite the lack of
locomotor effects in the presence of cocaine, DAT knockouts do self-administer
cocaine [85], indicating contribution of a different system in the reward
mechanism. Identification of sites for cocaine binding and neuronal activation
implicated the 5-HT system [85], as further supported by the lack of conditioned
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place preference behavior (an indication of reward) in the DAT/SERT double
knockout mouse [86],
These knockout studies demonstrate the involvement of DAT in processes
related to modulation of DA concentrations and further substantiate its crucial
role in maintaining pre- and post-synaptic DA homeostasis. In addition, these
models demonstrate the complexity of the monoaminergic systems and the
contribution

of

various

mechanisms

in

mediating

psychostimulant

self

administration and reward.
Substrate and Ligand Binding Sites
The first step in the translocation process involves the selective binding of
substrates and ions to DAT. Inhibitors also bind to DAT but they are unable to be
transported across the plasma membrane. A number of distinct structural
elements present in substrates and inhibitors are involved in the high affinity
recognition of their binding site on DAT. DA most likely appears in cationic or
zwitterionic form at physiological pH, where the catechol ring is postulated to be
necessary for binding, and the amine side chain is thought to mediate the
conformational switches necessary for transport [87-89], Additionally, the majority
of the non-DA substrates are phenethylamine analogues that contain a
protonated amine group, apparently involved in their recognition by the
transporter [89], In the case of cocaine the tropane ring, the bridged tropane
nitrogen and the phenyl-ester moiety represent essential elements for normal
DAT binding [74]. Together the structural features of DA, phenethylamine
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derivatives, and cocaine are potentially recognized by DAT through a variety of
interactions involving charged, aromatic and polar residues [90].
The DAT interaction domains for substrates and uptake-blockers have
been extensively studied through a variety of approaches in an attempt to obtain
insight

into

the

structural

implications

of

the

translocation

pathway.

Understanding the relationship between structure and function at DAT is crucial
in the development of pharmacotherapy directed against drug abuse and DArelated syndromes. According to these studies the active sites reside within the
TM domains, with the loops functioning in a structural/conformational role.
Traditional binding and uptake experiments suggested that the recognition site
for DA and inhibitors was indistinguishable or mutually exclusive [91]. However,
evidence from chimeras and site-directed mutagenesis implicate several distinct
and shared domains in substrate and blocker binding.
DAT/NET constructs revealed the involvement of TMs 1-3 in both DA and
blocker interaction, and TMs 5-8 in the recognition of blockers only [92,93],
Additionally, human/bovine DAT chimeras demonstrated that the concomitant
presence of TM3 and TMs 6-8 was necessary for high affinity cocaine binding,
suggesting that several domains participate in the recognition of uptake blockers
[94,95].
More precise localization of the specific amino acids present in the active
site within these domains was achieved through site-directed mutagenesis. The
first DAT amino acid demonstrated to participate in interactions with both DA and
cocaine was D79, located in the middle of TM1 [96], Interestingly, D79 is one of
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only two negatively charged residues located within DAT TMs and further it is
conserved within the monoamine NSSs. Replacement of D79 with alanine,
glycine or glutamate results in profound decreases in DAT affinities for DA and
the cocaine analogue CFT (2ft-carbomethoxy-3fJ-(4-fluorophenyl)tropane) [96].
TM1 additionally contains the residues F76 and W84, which were demonstrated
to be involved in cocaine binding by site-directed mutagenesis [97,98]. V152 is
predicted to lie within DAT TM3 and analysis of its replacement to isoleucine
supports participation in cocaine analogue binding [99], The TMs 6-8 residues
D313, F320, G323, Y335, D345, and D436 have also been implicated in
mechanisms involved in transport and inhibitor binding [97,98,100,101].
Although these domains are distant in the primary structure of DAT, their
involvement in substrate and blocker binding suggests they lie close together in
the tertiary structure and are part of a common binding pocket in DAT. Additional
evidence for the three-dimensional juxtaposition of domains was provided by the
identification of an endogenous extracellular zinc (Zn2+) binding site in DAT.
Coordination of Zn2+ by residues H193 in EL2, and H375 and E396 in EL4
requires an ideal distance of 4 A among them, positioning these domains in close
proximity in the three-dimensional arrangement of the protein [102-104].
Engineering artificial Zn2+ binding sites into DAT has been useful to further define
secondary and tertiary structure at the extracellular side of TMs 7 and 8, and to
identify residues involved in the conformational changes related to the transport
mechanism [105-107].
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Photoaffinity Labeling Strategy
In addition to the use of reversible competitive analogues and the above
described approaches, the functional domains and the active site in DAT have
been studied using photoaffinity ligands. Photoaffinity labeling enables direct
probing of the target protein through a covalent bond, which is photochemically
introduced between a ligand and its specific receptor. This method requires the
use of a bioactive ligand analogue with high affinity for the recognition site that
contains a light-sensitive moiety. The action of ultraviolet (UV) light produces a
highly reactive species that binds irreversibly to the biological receptor at or near
the active site [108,109].
A number of structurally diverse photoaffinity probes have been used to
study DAT, including structural analogues of cocaine, GBR

12909 and

benztropine. These analogues are composed by their cognate pharmacophore
core containing the essential structures for reversible binding to DAT, in addition
to a photoactivatable iodo-azido moiety, where the azido (N3) is the reactive
group that enables irreversible attachment and the reactive iodine ([125l] serves
as a tracer (Figure 8). With this technique, the radiolabeled analogues are
covalently incorporated into DAT and subjected to peptide mapping in order to
localize the attachment site. For the peptide mapping approach, photolabeled
DATs are subjected to protease treatment for relatively short periods of time,
after which large, well-defined fragments are generated. These fragments are
then analyzed by immunoprecipitation using antibodies directed against specific
epitopes in DAT, followed by sodium dodecyl sulphate polyacrylamide gel
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Figure 8. DAT Incorporation Domains for Photoaffinity Labels. A. Chemical
structures of the photolabels analyzed to date. [125I]DEEP and [125l]AD-96 are
GBR analogues, [125I]RTI 82 is a cocaine analogue, and [125I]GA 2-34 is a
benztropine analogue. B. Schematic diagram of hDAT indicating the domains of
ligand incorporation (magenta and blue cylinders), the relative positions of the
antibody 5 and 16 epitopes (colored bold lines), and the potential trypsin
cleavage sites (yellow circles).
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electrophoresis (SDS-PAGE), and autoradiography. Two DAT-specific antibodies
have been widely used for the immunoprecipitation procedures and have
enabled the identification of distinct iabeled regions within the protein. Antibody
16 is directed against amino acids 42-59 in the N-terminal tail, and antibody 5 is
generated against amino acids 225-238, located in EL2 (Figure 8).
Using photoaffinity labeling in combination with peptide mapping, two
distinct regions in DAT, TMs 1-2 and TMs 4-7, become consistently labeled by
structurally diverse uptake-blocker analogues. The GBR analogue [125I]DEEP
and the benztropine analogue [125I]GA 2-34 become incorporated in the TMs 1-2
region [110-112], and the cocaine analogue [125I]RTI 82 becomes incorporated in
TMs 4-7 [110,111]. Interestingly, the piperidine analogue [125]AD-96 becomes
incorporated into both of these regions [113] (Figure 8). This represents
additional evidence supporting the proximity of these domains in the threedimensional structure of DAT, and implies that uptake-blockers bind to a
common pocket composed of multiple DAT regions.
Photolabeling, Chemical Cleavage and Site-Directed Mutagenesis
Specific characterization of the exact amino acid to which these
compounds bind in DAT is limited by the enzymatic cleavage and antibody-based
approach. This method only allows positive identification of labeled fragments
that retain the antibody epitopes. Since DAT contains many potential cleavage
sites within or close to these epitopes, labeled fragments could be generated but
they would not be immunoprecipitated by the antibody. Recently, our laboratory
was able to localize the specific [125I]RTI 82 incorporation domain in DAT to TM6
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through the use of chemical cleavage in combination with site-directed
mutagenesis [114], Proteolysis of [125I]RTI 82 labeled DAT was performed using
cyanogen bromide (CNBr), which specifically cleaves at the C-terminal side of
methionine residues. hDAT and rDAT contain only 13 and 15 methionines,
respectively, scattered throughout the sequence. Additionally, based on the
antibody identification of TMs 4-7 as the [125I]RTI 82 attachment region, several
methionines were engineered into the hDAT sequence to create mutants in
combinations such that the size of the labeled fragments obtained by CNBr
treatment would be consistent with incorporation at a particular domain within this
region. This combination strategy allowed the positive identification of a region
containing residues from EL3, TM6, and IL3 as the [125I]RTI 82 labeled domain.
This finding was further confirmed by subjecting the labeled fragment obtained by
CNBr cleavage to a second round of digestion using the enzyme Lys-C. This
generated a reduced-mass labeled fragment, consistent with TM6 being the
[125,]RTI 82 incorporation domain. This combination approach thus proved to be
an effective strategy to delineate the specific domains to which the photolabels
become incorporated in DAT.
The present studies describe the characterization and localization of the
binding

site

for

[125I]MFZ

2-24

(A/-[4-(4-azido-3-[125l]iodophenyl)butyi]-2-

carbomethoxy-3ft-(4-clorophenyl)tropane) in DAT using photoaffinity labeling,
peptide mapping, chemical cleavage and site-directed mutagenesis. [125I]MFZ 224 is a cocaine analogue whose pharmacophore is identical to that of [125I]RTI 82
but the phenyl-iodo-azido moiety is placed differentially within the cocaine core
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(Figure 9). Since these compounds share the essential structures for reversible
cocaine binding, they should bind in the active site with identical orientation, and
the differential positions of the reactive groups should provide distinctive
irreversible incorporation patterns within the pocket. This would allow the positive
identification of the TMs that constitute the binding pocket for cocaine in DAT,
and would provide an estimation of the proximity of these domains within the
pocket. In addition, a third cocaine analogue in these series of compounds,
[125l]JHC 2-48 (3-(4’-azido-3’-iodo-phenyl)-8-methyl-8-aza-bicyclo-[3.2.1]octane2-carboxylic acid methyl ester) was initially analyzed and characterized through
peptide mapping in comparison to [125I]MFZ 2-24 and [125I]RTI 82. [125I]JHC 2-48
contains the reactive group appended to the phenyl ring in the pharmacophore
(Figure 9), and the localization of its incorporation site will provide further
evidence for the identity of the domains that compose the binding pocket for
cocaine in DAT.
These studies additionally describe the binding characteristics and the
irreversible incorporation into DAT of the GBR analogue [125i]D-147 (1-{2-[(4Azido-3-iodo-phenyl)-phenyl~methoxy]-ethyl}-4-phenethyl-piperazine

oxalate)

using photoaffinity labeling and peptide mapping. [125I]D-147 is identical in
structure to the previously characterized GBR-like compound [125]DEEP, with the
iodo-azido reactive group attached in a different position with respect to the
piperazine pharmacophore (Figure 9). The comparison of the irreversible
attachment sites for these related compounds will provide essential information

40

Figure 9. Chemical Structures of Photoaffinity Labels. A. Cocaine and cocainebased photolabels are shown. [125I]RTI 82 attachment to DAT has been
previously characterized [110,111,114]. Incorporation profiles of [125I]MFZ 2-24
and [125I]JHC 2-48 into DAT are described in these studies. B. GBR 12909 and
GBR-based photolabels are depicted. Incorporation of [125I]DEEP into DAT has
b .e.i

previously

described

[110,111].

characterized in the present studies.
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about the components of the binding site for GBR-like compounds and will further
our understanding of how the TMs in DAT are three-dimensionally oriented.
Previous studies using both GBR and cocaine classes of compounds have
suggested that they share a common binding pocket composed of multiple TM
domains. The present studies represent the first time that photoaffinity labels
carrying identical pharmacophores will be used to directly compare their
incorporation patterns. The obtained results will allow for correlation of the
information obtained from identifying the attachment sites for both classes of
inhibitors, and to further analyze the degree of similarity or difference among their
binding sites.
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CHAPTER II
MATERIALS AND METHODS
Materials
Animals
Male Sprague-Dawley rats (175-300 g) were obtained from Charles River
Laboratories (Wilmington, MA) and were housed and treated in accordance with
regulations approved by +he University of North Dakota Institutional Animal Care
and Use Committee and the National Institutes of Health.
Reagents
[125I]MFZ 2-24,

[125I]RTI

82,

[125I]D-147,

and

[125I]JHC 2-48 were

synthesized by Dr. Amy Newman (NIDA), Dr. Mu-Fa Zou (NIDA), Dr. Joo Whan
Cha (NIDA) and Dr. Aloke Dutta (Wayne State University), and radioiodinated by
Dr. John Lever (University of Missouri) as previously described [115-118],
Trypsin, trypsin inhibitor, dopamine, (-)-cocaine, GBR 12909, nomifensine,
mazindol, desipramine, imipramine, citalopram, nisoxetine, fluoxetine and CNBr
were from Sigma-Aldrich (St Louis, MO). (+)-Cocaine was the generous gift of Dr.
Maarten E.A. Reith (New York University School of Medicine, New York, NY).
[3H]2li-carbomethoxy-3ft-(4-fluorophenyl)tropane (CFT) was from Perkin Elmer
Life and Analytical Sciences (Boston, MA). Protein A Sepharose CL4B beads,
[3H]dopamine, and high- and low-range Rainbow Molecular Weight Markers
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Markers were from Amersham Biosciences/GE Healthcare (Piscataway, NJ).
Electrophoresis reagents were from Bio-Rad (Hercules, CA). Human Embryonic
Kidney (HEK) 293 cells were from ATCC (Manassas, VA), HEK 293 cells
expressing hSERT were kindly provided by Dr. Randy Balely (Vanderbilt
University, Nashville, TN), and Lewis Lung Carcinoma Porcine Kidney (LLCPKi)
cells expressing rDAT were the generous gift of Dr. Gary Rudnick (Yale
University, New Haven, CT). Complete Mini protease inhibitor and FuGENE 6
transfection reagent were from Roche Applied Sciences (Indianapolis, IN). Cell
culture

reagents were from

Mediatech

(Herndon, VA); the QuikChange

Mutagenesis kit was from Stratagene (La Jolla, CA). Synthetic oligonucleotide
primers were purchased from Genscript Corporation (Piscataway, NJ), or MWG
Biotech Inc (High Point, NC). All other chemicals and reagents were from SigmaAldrich (St Louis, MO) or Fisher Scientific (Pittsburgh, PA).
Equipment
Centrifuges
A Beckman Avanti J-25 centrifuge with a JA 25.50 or a JA 16.250 rotor
was used to prepare rat striatal membranes and for purification of plasmids.
Beckman Microfuge R and Microfuge 18 centrifuges were used for general
microcentrifugation

under

refrigerated

and

non-refrigerated

conditions,

respectively. A Beckman J6-MI swinging bucket centrifuge with a JS 5.2 rotor
was used for Protein A Sepharose beads preparation and cell pelleting.
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Electrophoresis, electroelution and dialysis
Sodium dodecyl sulphate (SDS) poly-acrylamide gel electrophoresis
(PAGE) was performed using the Gibco/BRL Life Technologies Model V16 gel
system or the Bio-Rad Mini-Protean III electrophoresis device. Transfer of
electrophoresed proteins was performed using a Bio-Rad Mini trans blot
electrophoresis transfer cell. Electrical voltage and current for both processes
was monitored by the Gibco/BRL Life Technologies 250 EX power supply. Gels
were dried using a Bit-Rad Model 583 gel dryer.
Electroelution of proteins was performed using the Bio-Rad Model 422
Electroeluter with 3,500 MW cutoff membrane caps. Electroeluted proteins were
dialyzed using Pierce Slide-A-Lyzer® cassettes with 10,000 MW cutoff.
Spectroscopy
A Molecular Devices SpectraMax 190 plate reader was used to quantify
Bicinchoninic

acid

(BCA)

protein

assays

and

a

Beckman

DU640

spectrophotometer was used to quantify plasmid DNA. a rackard 1900CA or a
Beckman LS6500 liquid scintillation counter was used to analyze incorporation of
radioactivity during binding and uptake experiments.
Cell culture, molecular biology and miscellaneous equipment
Mammalian cells were grown and maintained in a Nuaire 2700-30 waterjacketed C 0 2 incubator, and sterilely managed in a Nuaire Class II type A/B3
laminar flow hood. An Eppendorf Mastercycier Personal thermocycler was
utilized to perform procedures involving Polymerase Chain Reaction (PCR). A
Polytron PT2100 homogenizer was used to homogenize rat striatum for
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membrane preparations. A Thermo Savant SpeedVac® evaporator was used to
dry dialyzed and CNBr digested samples. A Fotodyne ultraviolet (UV) lamp
model 3-6000 was used in photolabeling studies.
Methods
Photoaffinity Labeling
Rat Striatal Membranes
Male Sprague-Dawley rats (175-300 g) were decapitated and the striatal
tissue was immediately removed and weighed, after which it was placed in icecold sucrose-phosphate (SP) buffer (10 mM sodium phosphate piuc 0.32 M
sucrose, pH 7.4) and homogenized with a Polytron Homogenizer in setting 11 for
12-15 sec. Homogenate tissue was subjected to centrifugation at 20,000 xg for
12 min at 4 °C, and the resulting membranes were washed twice by
centrifugation in ice-cold SP buffer and resuspended to 20 mg/mL original wet
weight (o.w.w.). [125I]MFZ 2-24, [125I]RTI 82, [125I]D-147 and [125I]JHC 2-48
reaction mixtures were prepared in SP buffer, added to the membranes at a final
concentration of 5 nM, and incubated for 60 min at 0 °C to allow reversible
binding. For pharmacological competition studies, saturating concentrations (110 pM) of non-radioactive transporter inhibitors and substrates were added to the
binding mixture. Irreversible attachment of the photoaffinity ligands to DAT was
carried out by directly irradiating the sample with UV light (254 nm) for 45 sec at
a distance of 1 cm. The resulting photolabeled membranes were washed three
times by centrifugation with SP buffer and subsequently solubilized at 20 mg/mL
o.w.w. in SDS-PAGE sample buffer (60 mM Tris-HCI pH 6.8, 100 mM
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dithiothreitol, 10% glycerol, 2% SDS and 0.001% bromophenol blue) or SP buffer
for in situ proteolysis or 0.5% SDS sample buffer (60 mM Tris-HCI pH 6.8, 100
mM dithiothreitol, 10% glycerol, and 0.5% SDS) for immunoprecipitation.
hDAT/rDAT/hSERTExpressing Cells
Wild type hSERT, and wild type and mutant hDAT and rDAT cells were
plated onto 6-well plates and grown to 90-95% confluence. Growth medium was
removed and the cells were incubated with 5 nM radioligand reaction mixtures
prepared in Krebs Ringers HEPES (KRH) buffer (25 mM HEPES, 125 mM NaCI,
4.8 mM KCI, 1.2 mM KH2P 0 4, 1.3 mM CaCI2, 1.2 mM MgS04, 5.6 mM glucose,
pH 7.4) for 60 min at 22 °C to allow reversible binding. For cocaine displacement
studies, a 50 pM solution of cocaine was prepared in KRH buffer and added to
the binding mixture. The ligands were covalently incorporated into DAT by direct
irradiation with UV (254 nm) light for 45 sec at a distance of 1 cm. Photolabeled
cells were washed twice with 1 mL/well KRH and solubilized with 500 pL/well
Triton buffer (1% Triton X-100, 25 mM Tris base, 150 mM NaCI, 1mM EDTA)
supplemented with Complete Mini protease inhibitor at 0 °C for 30-45 minutes.
Lysates were centrifuged at 20,000 xg for 15 min at 4 °C and supernatants were
collected and used for further analysis.
Gel Purification, Electroelution and Dialysis
Solubilized radiolabeled DATs from rat striatal membranes or cells were
subjected to purification by SDS-PAGE on 10% tris-glycine gel systems. Gels
were dried and exposed to autoradiographic film for 6-16 h. The -8 0 kDa labeled
bands that correspond to DAT were excised, removed and rehydrated in 1X
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SDS-PAGE running buffer (25 mM Tris, 192 mM Glycine and 0.1% SDS).
Rehydrated gel pieces were subjected to electroelution at 10 mA/tube for 5.5 h,
and electroeluates were dialyzed against 1 L of MilliQ purified water for 20-24 h
followed by evaporation to dryness in a SpeedVac® concentrator.
In situ Trypsin Proteolysis
Photolabeled rat striatal membrane suspensions prepared at 20 mg/mL in
SP buffer were subjected to treatment for 10 min at 22 °C with equal volumes of
trypsin prepared in SP buffer at final concentrations of 10-200 pg/mL. At the end
of the incubation one volume of 1 mg/mL trypsin inhibitor was added to halt the
digestion process, followed by centrifugation at 20,000 xg for 12 min at 4 °C. The
resulting pellets were solubilized with 0.5% SDS sample buffer.
In solution Cyanogen Bromide Digestion
Dried electroeluted and dialyzed extracts were incubated for 24 h at 22 °C
in the dark with 0.1 mL of 1M CNBr prepared in a 70% formic acid solution or
with 70% formic acid solution alone. Quenching of the reaction was achieved by
addition of 0.9 mL MilliQ water followed by evaporation to dryness in a
SpeedVac® concentrator. The samples were subjected to three additional rounds
of suspension in water and drying to remove residual volatile acidity. The final
dried samples were resuspended in either sample buffer for analysis by
electrophoresis and autoradiography, or immunoprecipitation buffer (50 mM TrisHCI, 0.1% Triton X-100, pH 8.0) (IPB) for analysis by immunoprecipitation,
electrophoresis and autoradiography.
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Immunoprecipitation, Electrophoresis and Autoradiography
Solubilized radiolabeled DATs or DAT fragments were subjected to
epitope-specific immunoprecipitation as described previously [112,113] with
minor modifications, using antiserum 16 generated against amino acids 42-59, or
antiserum 5 generated against amino acids 225-238. Briefly, protein A sepharose
beads were hydrated and washed three times with IPB, and resuspended in IPB
plus 0.05% sodium azide (NaN3). Polyclonal antibody (20 pg) was bound to the
hydrated beads for 3-6 h at 4 °C with rotation followed by three washes with IPB.
Alternatively, protein A sepharose beads were hydrated in triethanolamine (TEA)
buffer (0.2 M TEA, pH 8.0), incubated with polyclonal antibody for 45 min at 22
°C and washed twice with TEA buffer; the antibody was cross-linked to the beads
by incubation with DMP (Dimethyl pimelimidate) for 45 min at 22 °C, after which
the beads were washed twice with 100 mM Tris pH 8.0, rinsed with IPB and
resuspended in IPB plus 0.05% NaN3. Samples were incubated with either bead
slurry for 3 h at 4 °C with rotation, suDsequently washed four times with IPB and
eluted with sample buffer.

For peptide competition experiments,

diluted

antibodies were preabsorbed with 50 pg/mL of peptide 16 or peptide 5 before
sample addition. Total and immunoprecipitated samples were electrophoresed
on SDS-PAGE 9-16%, 16%, 18% or 20% gels at 6-8 mA for 16 h, followed by
autoradiography using Hyperfilm™ MP or Kodak BioMax MS film for 1 to 4 days
at -80 °C. Low- and high-range Rainbow Markers were used as molecular mass
standards.
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Immunoblot Analysis
Solubilized rat striatal membranes or cell lysates were subjected to
separation by SDS-PAGE on 10%, 4-20%, or 10-20% tris-glycine polyacrylamide
gels at 125 V for 2 h. Separated proteins were transferred to 0.45 or 0.2 pm
polyvinylidene fluoride (PVDF) membranes at 100 V for 2 h in transfer buffer (10
mM Tris,

100 mM glycine, 0.01% SDS and

10% methanol) at 4 °C.

Subsequently, PVDF membranes were blocked for >3 h with 3% bovine serum
albumin (BSA) in phosphate buffer saline (PBS) (BSA/PBS buffer) at 4 °C. DAT
protein was detected with the hDAT specific rat monoclonal antibody MAB 369
(Chemicon/Millipore, Temecula, CA) generated against DAT N-terminal tail. A
1:1000 dilution of MAB 369 in BSA/PBS buffer was incubated with the blocked
PVDF membranes for 1 h at 22 °C. Removal of unbound antibodies was
achieved by washing the membranes four times with PBS/Tween buffer (PBS
plus 0.1% Tween-20). Detection of the primary antibody was achieved by
incubating the membranes with a 1:20,000 dilution of alkaline-phosphatase
linked anti-rat IgG (Sigma-Aldrich) for 1 h at 22 °C, followed by removal of
unbound antibodies by washing the membrane four times with PBS/Tween
buffer. The membranes were developed using the alkaline phosphatase
substrates lmmun-Star™AP (Bio-Rad) for 5 min or 5-bromo-4-chloro-3-indolyl
phosphate/nitro blue (BCIP/NBT) (Sigma-Aldrich) for 5-10 min. Immun-Star™
treated membranes were visualized with a Boehringer-Manheim Lumi Imager
and quantified using LumiAnalyst 3.0 software. BCIP/NBT treated membranes
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were dried, scanned on an Epson 1200 scanner as tagged image format files
(TIFF) images, and quantified using LumiAnalyst 3.0 software.
QuikChange® Site-Directed Mutagenesis
An N-terminal wild-type (WT) 6xHis-human (h) DAT in a pcDNA 3.1/His®B
vector was used as the starting template for mutagenesis. Selected residues
were mutated using the QuikChange® method in order to generate or eliminate
CNBr cleavage points. The oligonucleotide primers utilized for codon substitution
were designed through the PrimerX website (http://bioinformatics.org/primerx)
and synthesized by GenScript Corporation or MWG Biotech (Appendix B). The
reaction mixture was prepared in 200 pL PCR tubes following the parameters in
Table 1. The reaction was initiated by the addition of 1 pL of PfuTurbo DNA
Polymerase (2.5 U/pL) and cycled according to the cycling parameters described
in Table 2.
Table 1. QuikChange® Reaction Mixture
Volum e (pL)

Reagent

5

10X Reaction buffer (100 mM KCI, 100 mM(NH4)2S04, 200 mM TrisHCI pH 8.8, 20 mM MgS04, 1% Triton® X-100,1 mg/mL nuclease-free
BSA)

20

Template DNA (5 ng/pL)

1.25

Oligonucleotide primer #1 (125 ng)

1.25

Oligonucleotide primer #2 (125 ng)

1

dNTP mix

21.5

Double distilled DNAse free H20

50

Final Volume
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Table 2. QuikChange® Thermal Cycling Parameters
C y c le s

T e m p e ra tu re

T im e

1

1

95 °C

30 seconds

2

16

95 °C

30 seconds

55 °C

1 minute

0
00
CD

8 minutes

O

Segm ent

Following the thermal cycling process, 1 pL of the Dpnl restriction enzyme
(10 U/pL) was added to the reaction mixture and incubated at 37 °C for 1 h to
degrade the template supercoilea double-stranded DNA. The resulting 6xHishDAT pcDNA 3.1/His®B plasmid (Figure 10) was transformed into either
NovaBlue competent cells

(Novagen) or XL1-Blue

supercompetent cells

(Stratagene) according to the manufacturers’ guidelines.
Plasmid Amplification and Isolation
Transformed cells were plated on 1.5% agar plates containing 100 pg/mL
carbenicillin, followed by incubation at 37 °C for >16 h to obtain colonies. Colony
development was achieved by collection of one colony of cells from the selective
agar followed by growth in Glucose M9Y medium complemented with 100 pg/mL
carbenicillin. The plasmid DNA was isolated using the PureYield® Plasmid
Midiprep System (Promega), visualized through separation by electrophoresis on
c 1% agarose gel (0.5 pg/mL ethidium bromide) with the GrabIT Annotating
Grabber 2.04.6 (UVP Inc, Upland, CA), and quantified using the BioRad
Molecular Analyst™ software version 1.0 (1992-1996). Additionally, the DNA
concentration of the sample was measured by spectrophotometry at 260 nm
using the following formula: [DNA (pg/mL)] = A26o (50) (dilution factor). The final
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Figure 10. Schematic Diagram of the 6xHis-hDAT pcDNA 3.1/His B Plasmid.
The major regions of this fusion vector are depicted here. Shown are the CMV
immediate-eariy

promoter (yellow),

the

oxriistidine

sequence,

the

hDAT

sequence (blue), the SV40 early promoter (green), the Neomycin resistance
gene (purple), the Ampicillin resistance gene (magenta), and the polyadenylation
signal (black and white). Additionally, the restriction sites used to insert the hDAT
coding sequence are indicated.
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concentration of the plasmid DNA was obtained as an average of the two
methods used for quantification. To verify the presence of the desired mutation(s)
oligonucleotide primers were generated (Appendix C), the DAT insert was
sequenced by Northwoods DNA (Solway, MN) or Alpha Biolabs (Sunnyvale, CA)
and analyzed using Vector NTI software (Invitrogen).
Transfection of HEK 293 Cells
Stable transfection of Human Embryonic Kidney (HEK) 293 cells was
achieved by growth of parental HEK 293 cells to 40-60% confluency in T25 flasks
and transfection through the FuGENE 6 reagent in a 3:1 FuGENE 6 to DNA ratio
mixture (Table 3). The FuGENE 6/DNA mixture was prepared in serum-free
complete medium (Dulbecco’s modified Eagle’s medium-DMEM, 2 mM Lglutamine), gently mixed and incubated at 22 °C for 15-30 min.
Table 3. FuGENE 6 Transfection Reaction Volumes
M utants
R eagents

M 116A

M 111L/M 116L

(HL)

L80M/

I67M /

M 111L/M 116L

M 111L/M 116L

FuGENE 6

12

12

12

12

DNA (4 pg)

21

14

11

19

(193 ng/pL)

(300 ng/pL)

(356 ng/pL)

(212 ng/pL)

Media

217

234

227

219

Final Volume

250

250

250

250

(Concentration)

Following incubation, the transfection reaction mixture was added in a
drop-wise manner to the cell medium in the T-25 flask containing the parent cells
and placed in the incubator at 37 °C until 90-95% confluency is reached. For
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selection of effectively transfected cells, the original medium was removed, the
cells were split 1:2, and selection medium was added (DMEM, 10% fetal bovine
serum-FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 pg/mL streptomycin,
and 600 pg/mL G418). Cells were kept under selection conditions for 2-3 days,
dead cells were removed, flasks were rinsed with Hanks Balanced Salt Solution
(HBSS), and selection medium was added. Cells were grown in selection
medium for ~2 weeks, after which growth medium (DMEM, 10% FBS, 2 mM Lglutamine, 100 U/mL penicillin, 100 pg/mL streptomycin, and 250 pg/mL G418)
was added.
Expression of mutant DATs was verified through immunoblot analysis of
cell lysates with MAB 369 antibody. Lysates were obtained by solubilizing cells in
Triton buffer for 30-45 min at 4 °C, and immunoblotted as described above. The
protein concentration of the lysates was measured by spectrophotometry using
the BCA method.
Cell Culture and Cell Freezing
Parental HEK 293 cells were grown and maintained in serum-free
complete medium. 6xHis-hDAT HEK 293 cells were selected, grown and
maintained in complete medium with either 250 or 600 pg/mL G418. Growth and
maintenance was performed in T-75 flasks at 37 °C in an incubator gassed with
5% C 0 2/95% 0 2.
Once DAT expression was verified by immunoblotting with stably
transfected cells, stock aliquots were prepared for freezing. Cells were cultured in
T-75 flasks until 95-100% confluency was achieved. Once confluent, cells were
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collected, pelleted, resuspended in 2-3 mL of freeze medium (10% Dimethyl
Sulfoxide-DMSO), and aliquoted in properly labeled cryovials. Aliquots of cells
were gently frozen for 24 h in a Nalgene Cryo 1 °C container, and subsequently
stored in liquid nitrogen.
Functional Assays
Whole Cell [3H]CFT Binding and [3H]DA Uptake
HEK 293 cells expressing WT and mutant 6xHis-hDAT were grown in 24well plates until 75-80% confluency was reached, and washed twice with ice-cold
KRH buffer. For binding assays cells were incubated in quadruplicates with 5 nM
[3H]CFT in KRH for 2 h at 0 °C, subsequently rinsed twice with KRH, and
solubilized in 1% Triton X-100. For uptake assays, cells were assayed in
triplicate for DA transport using a 3 pM DA mixture containing 10 nM [3H]DA in
KRH, and with 30 pM (-)-cocaine to determine non-specific uptake. Assays were
carried out for 9 min at 37 °C and stopped by rinsing cells with ice-cold KRH
followed by solubilization in 1% Triton X-100. Following solubilization, radioactive
binding and uptake lysates were added to 3 mL of scintillation fluid EcoScint A
followed by analysis by liquid scintillation counting at 52% efficiency. In order to
obtain the IC50 values for cocaine inhibition of [3H]CFT binding and [3H]DA
uptake, assays were performed in the presence of 10'11 - 10^ M (-)-cocaine.
Rat Striatal Membrane [3H]CFT Binding Competition Assay
In order to determine the binding affinity of the novel ligand D-147 for
DAT, a [3H]CFT binding competition assay was performed in rat striatal
membrane preparations. Rat striatal tissue was homogenized in SP buffer, and
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homogenates ce.itrifuged. The resulting membranes were resuspended at 10
mg/mL o.w.w. in the same buffer.

To inititate the binding competition assay,

triplicate samples of membranes were added to tubes containing 10'10-10'r' M
concentrations of D-147, and 1 nM [3H]CFT prepared in SP buffer, followed by
incubation on ice for 2 h. Membranes were then collected and washed three
times with 5 mL of SP buffer using a Brandel tissue harvester over Whatman
GF/B glass fiber filters soaked for 1 h in 0.1% BSA/0.05% Polyethylemine (PEE)
in PBS. Bound radioactivity was quantified by liquid scintillation counting at 52%
efficiency.
Statistical Calculations and Graphs
The determination of the cocaine IC50 for inhibition of [3H]DA uptake or
[3H]CFT binding to DAT in WT and mutant hDAT HEK 293 cells, and the
determination of the D-147 IC50 for binding to DAT in rat striatal tissue were
performed using non linear regression analysis with Prism 3.0 software
(Graphpad Software, San Diego, CA). Values were statistically analyzed using
Analysis of Variance (ANOVA) with Tukey’s Multiple Comparison Test.
Energy Minimization Calculations
Intramolecular distances and energy minimization calculations were
carried out by Dr. Amy Newman (NIDA-IRP). The intramolecular distances in
[125I]MFZ 2-24 were obtained using the molecular modeling program SYBYL 6.7
(Tripos Inc.) with the CFT crystal structure as a template. Energy minimizations
were performed by conjugate gradient method until a convergence gradient of
0.001 kcai/mol/A was achieved.
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CHAPTER III
RESULTS
Pharmacology of [125I]MFZ 2-24 incorporation into DAT
The photoaffinity label [125I]MFZ 2-24 is a cocaine analogue whose
structure contains tropane and phenyl rings, known essential elements for
cocaine binding to DAT. [12ol]MFZ 2-24 is structurally identical to the previously
characterized [125I]RTI 82 [114], except for the position of the pheuyl-iodoazido
reactive group with respect to the cocaine pharmacophore (Figure 11). Synthesis
and radioiodination of MFZ 2-24 have been previously described and its IC50
value for displacement of [3H]CFT in rat striatum was shown to be 33.0 ± 4.7 nM
[115,116], indicating high affinity for DAT.
Incorporation of [125I]MFZ 2-24 into rat striatal DATs was evaluated in the
presence of a number of uptake blockers and the physiological substrate DA, in
order to determine its pharmacological specificity for binding to DAT. Labeling
was prevented when binding was carried out in the presence of DA or the DA
uptake inhibitors (-)-cocaine, mazindol, GBR 12909 and nomifensine, but was not
modified by the inactive enantiomer (+)-cocaine, the NET blocker desipramine or
the SERT blocker imipramine (Figure 12). These results demonstrate that
[125I]MFZ 2-24 irreversibly attaches to DAT and that the compounds used in
these studies act as competitive

inhibitors by preventing the reversible
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Figure 11. Chemical Structure of Cocaine-Based Photoaffinity Labels. Cocaine
and the analogues used in these studies are shown. The phenyl-iodoazido
moiety that allows the covalent incorporation into the protein is attached to the
tropane ring C2 carbon in [125I]RTI 82, to the tropane bridge nitrogen in [125I]MFZ
2-24, and to the phenyl ring in [125I]JHC 2-48.
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Figure 12. [125I]MFZ 2-24 Photoaffinity Labeling Displays DAT Pharmacological
Specificity. Rat striatal membranes were photolabeled with [125I]MFZ 2-24 in the
presence of the indicated compounds [10 pM final concentrations, except
imipramine (1 pM) and dopamine (100 pM)]. After labeling, samples were
immunoprecipitated with antibody 16 and subjected to analysis by SDS-PAGE
and autoradiography.
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incorporation of the ligand. This evidence supports the assumption that the
irreversible incorporation site is located in or near a DAT domain of significant
pharmacological importance.
Peptide Mapping of the DAT [125I]MFZ 2-24 Incorporation Site by Trypsin
Proteolysis
Trypsin is a serine protease that cleaves proteins at the carboxyl side of
lysine and arginine residues. The DAT sequence contains several potential
trypsin sites (Figure 13), but for our peptide mapping studies using membrane
preparations, only those located in the interhelical loops are accessible for
enzymatic cleavage. In addition, the presence of both the antibody epitope and
the attached radioactive label is essential for a labeled fragment to be detected
by this approach. Tryptic maps of [125I]RTI 82 and [125I]DEEP labeled rat striatal
membranes showed cleavage at the EL2 residue R218 with subsequent
generation of two distinctive fragments that originate N- and C-terminal to this
amino acid. Visualization of a glycosylated 45 kDa [125I]DEEP fragment that
immunoprecipitates with antibody 16 (against residues 42-59), and a nonglycosylated 32 kDa [125I]RTI 82 fragment that is precipitated by antibody 5
(against

residues

225-238)

(Figure

13)

demonstrates

the

differential

incorporation of these ligands into discrete domains in DAT [111], This strategy
was also utilized to delineate the attachment sites for a variety of structurally
diverse compounds, which became incorporated into one or both of these
domains (Figure 8), supporting the hypothesis that TMs 1-2 and TMs 4-7
contribute at least in part to form a common binding pocket for various classes of
inhibitors [reviewed in 119].
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Figure 13. Potential Trypsin Cleavage Sites and Antibody Epitopes in rDAT.
Schematic diagram of rDAT showing the arginine (R) and lysine (K) residues as
the potential trypsin proteolysis sites (yellow). The N-terminal antibody 16 is
directed against residues 42-59 (magenta) and the EL2 antibody 5 reacts against
residues 225-238 (blue).
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In order to delineate the [125I]MFZ 2-24 irreversible incorporation profile on
DAT, a tryptic peptide map was performed in parallel with [125I]RTI 82 for direct
comparison of their incorporation sites. Rat striatal membranes were photoaffinity
labeled with [125!]MFZ 2 24 and [125I]RTI 82, and subjected to in situ trypsin
proteolysis followed by immunoprecipitation with N-terminal antibody 16 and EL2
antibody 5, electrophoresis on a 9-16% gel and autoradiography (Figure 14).
Cleavage of [125I]MFZ 2-24 labeled DATs generated a prominent 45 kDa
fragment that precipitates with antibody 16 and a very faint 32 kDa fragment that
precipitates with antibody 5. These results indicate that incorporation of [125I]MFZ
2-24 occurs N-terminal to R218, in a DAT domain containing TMs 1-3. In
contrast, proteolysis of [125I]RTI 82 labeled DATs produced the previously
characterized 32 kDa fragment that is precipitated by antibody 5, and no
detectable antibody 16 precipitable fragments (Figure 14).
[125I]MFZ 2-24 labeled rat striatal membranes were treated with increasing
concentrations of trypsin to more precisely localize the incorporation of the ligand
into DAT. In addition to the 45 kDa fragment, a 16 kDa fragment that
immunoprecipitated

with

antibody

16

was

observed

at

high

trypsin

concentrations, consistent with cleavage at IL1 (Figure 15A). To validate the DAT
origin of these fragments, photoaffinity labeling was performed in the presence of
10 pM (-)-cocaine, followed by tryptic proteolysis and immunoprecipitation with
antibody 16 (Figure 15A). [125I]MFZ 2-24 covalent labeling of the intact DAT, and
the 45 kDa and 16 kDa fragments (lanes 1, 3, 5 and 7) was completely displaced
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Figure 14. [125I]MFZ 2-24 and [125!]RTI 82 Attach to Distinct Domains in DAT.
Upper panel: Rat striatal membranes labeled with either [125I]MFZ 2-24 or
[125I]RTI

82

were

treated

with

or

without

50

pg/mL

trypsin

and

immunoprecipitated with antiserum 16 or 5, as indicated. Lower panel: Schematic
diagram

of rDAT showing

predicted

structure

and

membrane topology.

Transmembrane (TM) domains are shown as cylinders, the trypsin cleavage site
on EL2 (R218) is shown as a yellow circle, and antibody epitopes are indicated
by

colored

bold

lines

with

numbers.

Arrows

indicate

relationship

of

autoradiograph fragments to domains in schematic DAT. Cleavage at R218
generated an N-terminal 45 kDa fragment labeled with [125I]MFZ 2-24 that
originated from TMs 1-3 (magenta), and a C-terminal 32 kDa fragment labeled
with [125I]RTI 82 that originated from TMs 4-12 (blue).
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Figure 15. The Cocaine Analogue [125I]MFZ 2-24 Attaches to TMs 1-2 Domain in
DAT. A. Rat striatal membranes were labeled with [125I]MFZ 2-24 in the presence
(lanes 2, 4, 6, 8) or absence (lanes 1, 3, 5, 7) of 10 pM (-)-cocaine, treated with
(lanes 3-8) or without (lanes 1-2) increasing concentrations of trypsin and
subjected to immunoprecipitation with antiserum 16, followed by electrophoresis
and autoradiography. Full-length DAT protein migrates at ~80 kDa (arrow a), and
together with the 45- and 16-kDa N-terminal fragments (arrows b and c), they
display cocaine displacement of labeling. B. [125I]MFZ 2-24 labeled rat striatal
membranes

were

subjected

to

trypsin

(100

pg/mL)

proteolysis

and

immunoprecipitation with antibody 16 (lane 1), antibody 16 preabsorbed with
peptide 16 (lane 2) and antibody 16 preabsorbed with peptide 5 { ane 3),
demonstrating the immunological specificity of the precipitation of the 45- and 16kDa N-terminal fragments. C. Schematic diagram of rDAT highlighting the
incorporation domain of [125I]MFZ 2-24 (magenta). The trypsin sites that originate
the labeled fragments, R123, K132 and R218, are shown as yellow circles and a
colored bold line indicates antibody 16.
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by cocaine (lanes 2, 4, 6 and 8), demonstrating that the origin of the fragments
resides within the cocaine binding site in DAT.
Additionally, the immunological specificity of the [125I]MFZ 2-24 labeled
fragments was verified by preabsorbing antibody 16 with the immunizing peptide
or

the

non-immunogenic

peptide

5

before

subjecting

the

samples

to

immunoprecipitation (Figure 15B). Trypsin treated labeled rat striatal membranes
were immunoprecipitated

with antibody

16 alone (lane

1), antibody

16

preabsorbed with peptide 16 (lane 2), and antibody 16 preabsorbed with peptide
5 (lane 3). Immunoprecipitation of the 45- and 16-kDa fragments with serum 16
(lane 1) was prevented by the presence of the antigenic peptide (lane 2) but not
affected by the unrelated peptide 5 (lane 3).
These results indicate that the [125I]MFZ 2-24 labeled 45 kDa fragment
obtained by trypsin proteolysis and immunoprecipitation originates from rDAT Nterminal to the EL2 residue R218 and includes TMs 1-3. More precise
localization by tryptic treatment generates an additional 16 kDa fragment,
consistent with cleavage at rDAT R123 or K __ und containing TMs 1-2 (Figure
15C). There ic. i possibility of labeled fragments smaller than 16 kDa being
produced by the tryptic treatment, but the proteolytic loss of the antibody epitope
did not allow their detection by immunoprecipitation. In contrast to the [125I]RTI 82
irreversible attachment to TMs 4-7, [125I]MFZ 2-24 becomes incorporated into the
N-terminal TMs 1-2 region in DAT, indicating that differential placement of the
phenyl-iodoazido

arm

in the cocaine
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pharmacophore

results

in

distinct

incorporation

patterns.

This

represents the first evidence for differential

incorporation of photoaffinity labels carrying identical pharmacophore. In addition,
these findings strongly support the hypothesis of three-dimensional proximity
between the regions encompassing TMs 1-2 and TMs 4-7 in the tertiary structure
of DAT, and directly implicate these domains in binding of the psychostimulant
cocaine.
Peptide Mapping of the DAT [125I]MFZ 2-24 Attachment Site by CNBr cleavage
In contrast to enzymatic proteolysis, chemical cleavage of proteins is
directed to less abundant residues, and consequently results in fewer and larger
fragments. One of the most commonly used agents for chemical proteolysis is
cyanogen bromide (CNBr), which cleaves at the C-terminal side of unoxidized
methionine residues. This digestion occurs with high specificity, few side
reactions, and average yields of 90-100% [120,121], The rat and human isoforms
of DAT contain a relatively low number of methionine residues, making them an
ideal target for the use of this method. The 13 methionines present in hDAT are
located at positions 1 and 11 within the N-terminal tail; 106, 111, and 116 in TM2;
272 in TM5; 371 in EL4; 414, 424, and 427 in TM8; 511 in IL5; and 569 and 571
in TM 12 (Figure 16, black circles). rDAT contains 2 additional methionines at
positions 173 in EL2 and 290 in EL3 (Figure 16, grey circles).
Within the TMs 1-2 domain in hDAT and rDAT there are five methionines
that represent potential CNBr cleavage sites. In order to characterize the CNBr
cleavage profile of [125I]MFZ 2-24-labeled DATs, HEK 293 cells expressing a 6xHistidine tagged hDAT and LLCPKi cells expressing rDAT were utilized. This
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Figure 16. Methionine Residues in DAT. Schematic diagram of hDAT showing
the TM domains (grey cylinders), the N-glycosylation sites in EL2 (branched
structures), the position of epitope 16 (highlighted in magenta), the 13
endogenous methionines (black circles), and positions of two additional
methionines present in rDAT (grey circles). Residues pertinent to these studies
have been selectively numbered (rDAT/hDAT).
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chemical fragmentation reaction requires the protein to be isolated, lacking salts
and SDS. Thus, a thorough purification procedure was performed in order to
have suitable samples for this reaction. For the first step, [125I]MFZ 2-24 labeled
rDAT and hDAT cell lysates were gel purified through SDS-PAGE. The
radioactive band located between the 66- and the 97- kDa markers was excised,
rehydrated and subjected to a second purification step by electroelution in order
to remove DAT from the polyacrylamide gel matrix. Electroeluates were dialyzed
against MilliQ-filtered distilled water (MilliQ H2O) to remove salts and SDS, and
the final aqueous sample containing isolated, denatured DATs was evaporated to
dryness. Labeled rDAT and hDAT samples were treated with or without 1M CNBr
in 70% formic acid for 24 h in the dark, washed twice and evaporated to dryness,
followed by SDS-PAGE analysis (Figure 17A). In the absence of CNBr, DATs
from rat and human origin display their original migration profile at ~80 kDa
(lanes 1 and 3), while in the presence of CNBr a labeled fragment at ~12 kDa is
stoichiometrically produced from both isoforms (lanes 2 and 4). This fragment is
consistent with cleavage at one or more of the TM2 methionines (M106, M111
and M116) and labeling occurring N-terminal to the cleaved residue (Figure 17B).
The next potential CNBr site in rDAT is located at position 173 in EL2, and if the
ligand were attached C-terminal to M116 in rDAT, the labeled fragment would be
~6 kDa in size; for hDAT the next potential CNBr methionine site is in TM5, at
position 272, and the size of the labeled fragment would be ~40 kDa (including
~25 kDa of glycosylation present in EL2). Thus, the presence of the 12 kDa
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Figure 17.CNBr Hydrolysis of [125I]MFZ 2-24 Labeled rDAT and hDAT. A. hDATHEK 293 and rDAT-LLCPKi expressing cells were labeled with [125I]MFZ 2-24
and lysates subjected to purification by SDS-PAGE on a 10% gel. The band
located between the 66- and the 97-kDa markers was excised, DATs were
extracted by electroelution and subsequently dialyzed against water, followed by
evaporation to dryness. Dried DATs were solubilized in 70% formic acid and
treated with (lanes 2 and 4) and without (lanes 1 and 3) 1M CNBr for 24 h in the
dark, followed by SDS-PAGE and autoradiography on an 18% gel. B. Schematic
diagram of DAT highlighting the TMs 1-2 domain labeled by [125I]MFZ 2-24 Nterminal to M116 (magenta). Black circles indicate the 13 methionine residues
common to hDAT and rDAT, and grey circles indicate the positions of the
additional 2 methionines present in rDAT.
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fragment in both rDAT and hDAT provides additional evidence for the attachment
of [125I]MFZ 2-24 in the TMs 1-2 domain, N-terminal to M116 (Figure 17B).
Site-directed Mutagenesis, CNBr and Antibody 16
Analysis of [125I]MFZ 2-24 Labeled hDATs
The CNBr approach proved to be useful in order to determine that
[125I]MFZ 2-24 attaches to DAT in a domain located N-terminal to M116, which
includes TM1 and almost all of TM2 (Figure 17B). If the incorporation site lies
anywhere in the short stretch of amino acids that separates the three
methionines in TM2, the resolution of the peptide mapping strategy does not
allow visualization of such a small fragment (<1 kDa). Thus a strategy involving
site-directed mutagenesis in conjunction with photoaffinity labeling and CNBr
peptide mapping, was implemented in order to more precisely determine the
specific [125I]MFZ 2-24 incorporation domain in DAT. Using this method two
hDAT mutants were generated, one containing a methionine to alanine mutation
at position 116 (M116A) and another containing simultaneous methionine to
leucine mutations at positions 111 and 116 (M111L/M116L). hDAT expression
levels in these mutants were analyzed by western blotting (Figure 18-upper
panel) and their [125I]MFZ 2-24 photoaffinity labeling pattern (Figure 18-lower
panel) was proportional to their expression levels. In addition, their functional
properties were assessed and they exhibited robust cocaine-blockable [3H]DA
transport and whole cell [3H]CFT binding (Table 4).
For these studies hDAT WT and TM2 mutants were labeled with [125I]MFZ
2-24 in the presence and absence of cocaine, subsequently gel purified and
subjected to CNBr digestion, followed by immunoprecipitation with N-terminal
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Figure 18. Expression and Photolabeling of TM1/TM2 Methionine Mutants. HEK
293 cells stably transfected with hDAT plasmids carrying the indicated mutations
were photoaffinity labeled with [125I]MFZ 2-24, solubilized in 1% Triton buffer and
assayed for total protein content. Equal amounts of solubilized protein were
separated by SDS-PAGE in a 4-20% gel, transferred to a 0.2 pm PVDF
membrane and blotted with monoclonal anti-hDAT MAB 369 (upper panel). The
blotted membrane was air-dried and subjected to autoradiography in order to
visualize the extent of photoaffinity labeling (lower panel).
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Table 4. Kinetic Properties of wild-type and TM1/TM2 Methionine Mutant hDATs.
Data are presented as mean ± S.E. (n=3). Values were statistically analyzed
using one-way ANOVA with Tukey’s Multiple Comparison Test.
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hD AT form

Cocaine
DA uptake

IC 50
[3H]CFT
binding

DA uptake

[3H]CFT
binding

p m o l m in '1 m g '1

p m o l m in '1

nM

WT

236.9 ± 13.2

2.54 ± 0.63

866.6 ± 102.7

169.5 ±38.8

M116A

146.2 ± 14.1

0.95 ±0.19

644.5 ±95.1

361.6 ± 15.4*

M111L/M116L

404.7 ± 41.4a

3.71 ±0.56

607.4 ± 76.1

122.6 ± 11.4

L80M/M111L/M116L

47.5 ± 2.9*

2.38 ± 0.69

144.6 ± 21.3a

104.4 ± 10.7

I67M/M111L/M116L

173.6 ± 12.9

2.53 ±0.15

705.2 ± 147.4

129.1 ± 15.2

ap < 0.01, relative to WT values
b p < 0.001, relative to WT values
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antibody 16, SDS-PAGE and autoradiography. Figure 19 shows the untreated
(70% formic acid only) samples (odd-numbered lanes) and the CNBr digestion
(even-numbered lanes) products. Cleavage of the wild type (WT) protein
generates a cocaine-displaceable labeled fragment that migrates at ~12 kDa as
previously demonstrated (lanes 2 and 4). Digestion of M116A and M 111L/M116L
hDATs originates cocaine-displaceable labeled fragments with migration patterns
essentially identical to the ones obtained for WT hDAT (Figure 19, lanes 6, 8, 10,
12). In addition, all the fragments are immunoprecipitated by antibody 16,
indicating the presence of the N-terminal epitope. These results verify that
{125I]MFZ 2-24 attachment occurs N-terminal to M106 (shaded domains in lower
panels) in hDAT. If the attachment would occur C-terminal to either M111 or
M106,

the

labeled

CNBr fragment obtained

from the

M116A and the

M111L/M116L mutants would contain residues between M111-M272 (~42 kDa)
and M106-M272 (~43 kDa) respectively, and would be separated from the Nterminal epitope. These findings

provided

additional detailed

information

regarding the attachment site of [125I]MFZ 2-24 in DAT and further validated the
CNBr mapping strategy, strengthened by the concomitant use with site-directed
mutagenesis and immunoprecipitation. The elimination of potential CNBr
cleavage sites allowed for the identification of TM1 and the extracellular-facing
portion of TM2 as the DAT [125I]MFZ 2-24 labeled region.
Localization of TM1 as the [125I]MFZ 2-24 binding site in DAT
The use of site-directed mutagenesis combined with CNBr digestion and
immunoprecipitation is a powerful approach to increase the existing knowledge of
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Figure 19. [125I]MFZ 2-24 Attaches to TMs 1-2 N-terminal to M106. hDAT HEK
293 cells expressing WT, M116A and M111L./M116L protein were labeled with
[125I]MFZ 2-24 in the presence or absence of cocaine and subjected to
purification by SDS-PAGE on a 10% gel. The band located between the 66- and
the 97 kDa markers was excised, and DATs were extracted by electroelution and
dialyzed against water, followed by evaporation to dryness. Dried DATs were
solubilized in 70% formic acid and treated with (lanes 2, 4, 6, 8, 10 and 12) and
without (lanes 1, 3, 5, 7, 9 and 11) 1M CNBr for 24 h in the dark at room
temperature.

Following

digestion,

samples were

immunoprecipitated

with

antibody 16 and subjected to SDS-PAGE on an 18% gel followed by
autoradiography. Schematic diagrams of each protein indicate the positions of
the methionine residues present in them as black circles, with the region of the
protein corresponding to the labeled fragments shown as magenta shading.
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epitope 16

the incorporation domain in DAT for the cocaine analogue [125I]MFZ 2-24.
To more precisely determine the exact domain to which this compound becomes
attached in the TMs 1-2 region in DAT, a series of methionine residues were
engineered at positions that would allow the production of distinctive fragments
upon CNBr cleavage. Using site-directed mutagenesis the leucine at position 80
and the isoleucine at position 67 were individually replaced by methionine in the
hDAT M111L/M116L mutant such that there would be only one methionine
(M106) remaining in TM2 and the exogenous methionines would be located in
TM1

(L80M/M111L/M116L)

and

the

N-terminal

tail

respectively

(I67M/M111L/M116L). These mutants expressed hDAT protein and incorporated
[125I]MFZ 2-24 at levels comparable to the WT protein, as demonstrated by
western blot analysis and photolabeling (Figure 18). Additionally, their functional
properties were assessed by determining the ICsofor cocaine inhibition of [3H]DA
transport and whole cell [3H]CFT binding (Table 4).
For these studies WT and TM1/TM2 hDAT mutants (M111L/M116L,
L80M/M111L/M116L and I67M/M111L/M116L) were photoaffinity labeled with
[125i]MFZ

2-24,

gel

immunoprecipitation

purified
with

and

digested

N-terminal

with

antibody

CNBr,
16,

followed

SDS-PAGE

by
and

autoradiography. Results in Figure 20 show the untreated (70% formic acid only)
samples (odd-numbered lanes) and the CNBr digestion (even-numbered lanes)
products. Cleavage of WT and M111L/M116L hDATs generates the previously
characterized -1 2 kDa fragment that contains epitope 16 (lanes 2 and 4).
Importantly, the CNBr digestion product of L80M/M111L/M116L displays faster

88

Figure 20. [125I]MFZ 2-24 Attaches to TM 1 Between Residues 67 and 80 . hDATHEK 293 celis

expressing WT,

M111L/M116L,

L80M/M111L/M116L and

I67M/M111L/M116L protein were labeled with [125I]MFZ 2-24 and subjected to
purification by SDS-PAGE on a 10% gel. The band located between the 66- and
the 97-kDa markers was excised, DATs were extracted by electroelution and
dialyzed against water, followed by evaporation to dryness. Dried DATs were
solubilized in 70% formic acid and treated with (lanes 2, 4, 6 and 8) and without
(lanes 1, 3, 5 and 7) 1M CNBr for 24 h in the dark at room temperature.
Following digestion, samples were immunoprecipitated with antibody 16 and
subjected to SDS-PAGE on a 20% gel followed by autoradiography. Schematic
diagrams of each protein denote the positions of the endogenous and
engineered methionines as black circles, with the region of the protein
corresponding to the labeled fragments shown as magenta shading.
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electrophoretic mobility than the fragments from WT or M111L/M116L proteins
and migrates at ~9 kDa (lane 6). In addition, this fragment is precipitated with
antibody 16. This indicates that the labeling occurs N-terminal to L80M (shaded
region, lower panel) because if the ligand attachment occurred C-terminal to this
residue the CNBr fragment would extend from L80M to M106 (-3 kDa), would not
contain the N-terminal epitope, and thus would not immunoprecipitate. The next
mutant analyzed, I67M/M111L/M116L, produced no precipitable CNBr fragment
(lane 8). This represents evidence of labeling occurring C-terminal to I67M and
separation of the N-terminal epitope from the labeled TM1 region (unshaded
region, lower panel). If the label were incorporated in the cytoplasmic N-terminal
tail, the fragment would contain the entire tail (-7 kDa) including epitope 16.
These results indicate that a 13 amino acid stretch of TM1, between residues 67
and 80, is the site of covalent incorporation in DAT for the cocaine analogue
[125I]MFZ 2-24.
Photoaffinity Labeling of SERT with [125I]MFZ 2-24 and [125]RTI 82
The transporter for the neurotransmitter serotonin (5-HT), SERT, belongs
to the NSSs family and shares high homology with DAT and NET. SERT is a
well-known target for treatment of mood disorders, such anxiety, depression, and
post-traumatic stress. Several classes of compounds such as cocaine, the
tricyclic antidepressants and the serotonin-specific reuptake inhibitors (SSRIs)
block SERT and inhibit its uptake activity [reviewed in 41]. The cocaine
analogues [125I]MFZ 2-24 and [125]RTI 82 were used to photoiabel hSERT
expressing HEK 293 cells in parallel with rDAT expressing LLCPKi celis (Figure
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Figure 21. [125I]MFZ 2-24 and [125]RTI 82 Label SERT. A. rDAT LLCPKi cells and
hSERT HEK 293 cells were subjected to photolabeling with [125I]MFZ 2-24 and
[125]RTI 82, followed by immunoprecipitation with antibody 16 (against amino
acids 42-59 in rDAT) or antibody 48 (against amino acids 605-630 in hSERT). B.
Photoaffinity labeling of hSERT with [125I]MFZ 2-24 displays appropriate
pharmacological specificity. hSERT FIEK 293 cells were photolabeled with
[125I]MFZ 2-24 in the presence of the indicated compounds. Photolabeled lysates
were immunoprecipitated with antibody 48 and subjected to analysis by SDSPAGE and autoradiography [122],
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20). Labeled bands at 70-80 kDa were visible in lysates from both cell lines.
Immunoprecipitation of lysates with the corresponding anti-DAT (antibody 16) or
anti-SERT (antibody 48) antibodies specifically pulled down radiolabeled proteins
(Figure 21 A). The pharmacological specificity of [12i]M F Z 2-24 incorporation into
SERT was evaluated in the presence of 5-HT reuptake inhibitors followed by
epitope-specific immunoprecipitation, SDS-PAGE and autoradiography. Covalent
labeling of SERT was prevented by the SERT blockers (-)-cocaine, citalopram,
imipramine, and fluoxetine, but not by (+)-cocaine, the DAT inhibitor GBR 12909
or the NET blocker nisoxetine (Figure 21B) (122]. These results represent the
first time a photoaffinity approach has been applied for SERT and further
demonstrate that SERT becomes effectively labeled by [125I]MFZ 2-24 and
[125I]RTI 82. This strongly suggests that the irreversible incorporation sites on
DAT and SERT for cocaine analogues are likely to be similar.
Pharmacology of [125I]JHC 2-48 Incorporation to DAT and SERT
The cocaine analogue [125I]JHC 2-48 is a novel photoaffinity ligand that
contains the cocaine pharmacophore structures present in both [125I]RTI 82 and
[125I]MFZ 2-24, with the phenyl-iodoazido reactive group appended to the cocaine
phenyl ring (Figure 11). Synthesis and radioiodination of JHC 2-48 were recently
described, and evaluation of its kinetic properties revealed high affinity for both
DAT and SERT [118].
Irreversible incorporation of [125I]JHC 2-48 into hDAT and hSERT was
analyzed in the presence of cocaine in order to determine the pharmacological
specificity of the photolabel for these transporters. hDAT or hSERT expressing

94

Figure 22. [125I]JHC 2-48 Photoaffinity Labeling of hDAT and hSERT Displays
Pharmacological Specificity. HEK 293 cells expressing hDAT or hSERT were
photolabeled with [125I]JHC 2-48 in the presence or absence of (-)-cocaine and
cells were solubilized. Lysates were subjected to immunoprecipitation with hDAT
and hSERT specific antibodies, followed by SDS-PAGE on a 10% gel and
autoradiography [118].
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cells were photoiabeled with [125I]JHC 2-48 in the presence or absence of
(-)-cocaine followed by immunoprecipitation, SDS-PAGE and autoradiography
(Figure 22). Labeling was prevented when binding was carried out in the
presence of (-)-cocaine, demonstrating [125I]JHC 2-48 incorporation at a
pharmacologically significant site in both DAT and SERT.
CNBr Analysis of [125I]JHC 2-48 Labeling in DAT
The use of CNBr cleavage for the analysis of DAT proteins photoaffinity
labeled with cocaine analogues has been demonstrated to be a powerful strategy
to delineate the attachment domains of these compounds [114]. In order to
initially analyze the incorporation pattern of [125I]JHC 2-48 in DAT, HEK 293 cells
expressing hDAT were photoiabeled with [125I]JHC 2-48, [125!]MFZ 2-24, and
[125I]RTI 82

for comparison purposes. Labeled proteins were gel purified,

digested with CNBr, and analyzed by SDS-PAGE followed by autoradiography
(Figure 23). Cleavage of [125I]RTI 82 labeled DATs produces the previously
characterized 6 kDa fragment containing TM6 (lane 2). Similarly, digestion of
[125I]MFZ 2-24 labeled protein generates the 12 kDa fragment containing TM1
(lane 4). Interestingly, the digestion product of [125I]JHC 2-48 labeled DATs
exhibits a pattern distinct from that of the related cocaine analogues (lane 6), with
absence of any distinguishable labeled fragment, suggesting that this ligand
becomes incorporated into a region in DAT that has not been previously
characterized. If TM3 was the attachment site of [125I]JHC 2-48 a ~45 kDa
labeled fragment originating from cleavage between M116 and M272 should be
present in the SDS-PAGE analysis of the CNBr fragments, but the absence of
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Figure 23. [125I]JHC 2-48 Incorporates to DAT Distinctively from [125!]RTI 82 and
[125I]MFZ 2-24. hDAT expressing HEK 293 cells labeled with [125I]JHC 2-48,
[125I]RTI 82, and [125I]MFZ 2-24 were subjected to purification by SDS-PAGE on a
10% gel. The band located between the 66- and the 97-kDa markers was
excised, DATs were extracted by electroelution and dialyzed against water,
followed by evaporation to dryness. Dried DATs were solubilized in 70% formic
acid and treated with (lanes 2, 4 and 6) and without (lanes 1, 3 and 5) 1M CNBr
for 24 h in the dark at room temperature, followed by SDS-PAGE on an 18% gel,
and autoradiography.
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any discernable labeled fragment in the CNBr map eliminates this possibility. On
the other hand, there are several methionine residues in the C-terminal half of
DAT at positions 414, 424 and 427 in TM8, and at positions 569 and 571 in
TM12 (Figure 16). [125I]JHC 2-48 attachment to a residue within the methionines
in any of these domains would generate CNBr fragments of 1 kDa or less that
would not be resolved by the SDS-PAGE method and are consistent with the
absence of labeled fragments in the initial mapping (Figure 23).
Functional properties of D-147
The GBR series of compounds were originally developed in the early
1980s and shown to possess high selectivity and affinity for DAT. GBR 12909
selectively inhibits DA uptake with an IC50 of ~1 nM, and is less potent at NET
and SERT. This compound exhibits unique neuropharmacological properties,
including slow dissociation from DAT and the ability to block cocaine self
administration in non-human primates [123,124], One of the first photoaffinity
labels developed and used to visualize and characterize DA uptake sites was the
GBR derivative [125I]DEEP (Figure 24) [125-127], Soon after DAT was cloned,
[125I]DEEP

was

used to map GBR binding sites and its attachment was

localized to the TMs 1-2 domain [110,111],
The photoaffinity label [125I]D-147 is an aryl-dialkyalpiperazine compound
whose structure derives from GBR 12909. [125I]D-147 is structurally identical to
[125I]DEEP, except for the position of the phenyl-iodoazido group with respect to
the piperazine pharmacophore (Figure 24). Synthesis of D-147 was performed by
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Figure 24. Chemical Structures of GBR-Based Photoaffinity Labels. The structure
of GBR 12909, an aryl-dialkylpiperazine dopamine uptake blocker, is shown with
its derivative photoaffinity labels. [125I]DEEP is a piperazine-based photoaffinity
ligand whose site of incorporation has been identified in TMs 1-2, [125]D-147 is
the piperazine analogue being characterized in these studies, with a structure
identical to [125I]DEEP except that the reactive iodo-azido group is placed on the
biphenyl moiety at the opposite end of the molecule. [125l]AD-96 is a piperidine
analogue, derived from GBR structures and previously characterized.
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Figure 25. D-147 Binds to DAT with High Affinity. Rat striatal membranes were
prepared at 10 mg/mL in SP buffer. To initiate the binding competition assay,
triplicate membrane samples were added to tubes containing 10'1o-10'5 M
concentrations of D-147 and 1 nM [3H]CFT, followed by a 2 h incubation on ice.
Membranes were collected and washed three times using a tissue harvester over
glass fiber filters. Bound radioactivity was quantified by liquid scintillation. The

IC 50 value was determined and graphed using non-linear regression analysis with
Prism 3.0 software.
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Dr. Aloke Dutta (Wayne State University, Ml) and the IC50 value for displacement
of [3H]CFT binding in rat striatum was found to be 26 nM (Figure 25).
Pharmacology of [125I]D-147 incorporation to DAT
Irreversible incorporation of [125I]D-147 to rat striatal DATs was assessed
in the presence of several structurally dverse compounds and the physiological
substrate DA, in order to determine its pharmacological specificity for DAT.
Photolabeling was prevented when binding was carried out in the presence of DA
or the DA uptake inhibitors (-)-cocaine, mazindol, GBR 12909 and nomifensine,
but was not modified by the inactive enantiomer (+)-cocaine, the NET blocker
desiDramine or the SERT blocker imipramine (Figure 26). These results
demonstrate that [125I]D-147 covalently

attaches

to

DAT

and

that

the

compounds used in these studies are competitive inhibitors and prevent the
reversible incorporation of the ligand to the transporter. These results support the
assumption that the irreversible incorporation site for uptake blockers is located
in or near a pharmacologically significant domain in DAT.
Peptide Mapping of the DAT [125I]D-147 Incorporation Site by Trypsin Proteolysis
In order to localize the irreversible incorporation site of [125I]D~147 on DAT,
a tryptic peptide map was performed. [125I]D-147 was used to photoaffinity label
rat striatal membranes, which were subjected to in situ trypsin proteolysis
followed by immunoprecipitation with N-terminal antibody 16 and EL2 antibody 5,
SDS-PAGE separation on a 9-16% gel, and autoradiography (Figure 27). Trypsin
digestion of [125I]D-147 labeled DATs resulted in a 45 kDa fragment and an
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Figure 26, [125I]D-147 Photoaffinity Labeling Displays DAT Pharmacological
Specificity. Rat striatal membranes were photolabeled with [125I]D-147 in the
presence of the indicated compounds [10 pM final concentrations, except
imipramine (1 pM) and dopamine (100 pM)]. After labeling, samples were
immunoprecipitated with antibody 16 and subjected to analysis by SDS-PAGE
and autoradiography.
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Figure 27. The GBR Analogue [125I]D-147 Attaches to Distinct Domains in DAT.
A. Rat striatal membranes were labeled with [125I]D-147, treated with (lanes 2-4
and 6-8) or without (lanes 1 and 5) increasing concentrations of trypsin and
subjected to immunopreciphation with antiserum 16 or antiserum 5, followed by
electrophoresis on a 9-16% gradient gel and autoradiography. Arrows a, b, c and
d indicate the positions of the [125I]D-147 labeled fragments.
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additional 16 kDa fragment that immunoprecipitate with antibody 16 (lanes 2-4,
arrows a and b), consistent with incorporation at the TMs 1-2 region.
Interestingly, precipitation of the same trypsin-digested [125I]D-147 labeled
sample with antibody 5 isolated a 32 kDa fragment with an additional ~16 kDa
fragment (lanes 6-8, arrows c and d) consistent with attachment to the TMs 4-6
domain.
Additionally, the immunological specificity of the [125I]D-147 labeled
fragments was verified by preabsorbing the antibodies with their respective
immunizing peptides or non-immunogenic peptides before subjecting the
samples to immunoprecipitation (Figure 28). Trypsin treated labeled rat striatal
membranes were immunoprecipitated with antibody 16 alone or antibody 5
alone, antibody 16 preabsorbed with peptide 16 or antibody 5 preabsorbed with
peptide 5, and antibody 16 preabsorbed with peptide 5 or antibody 5
preabsorbed by antibody 16, as indicated. Immunoprecipitation of the 45 kDa
fragment with serum 16 was prevented by the presence of the antigenic peptide
but not affected by an unrelated peptide. Precipitation of the 32 kDa fragment by
antibody 5 was prevented in the presence of the immunizing peptide but
remained unmodified by an irrelevant peptide.
The relative amount of [125!]D-147 incorporation into DAT appeared to be
larger for the TMs 4-6 region than for the TMs 1-2 region, as estimated from the
intensities of the respective 32- and 45-kDa fragments, compared to the fulllength protein. This suggests an apparently increased incorporation of [125I]D-147
into the C-terminal half of DAT, similar to [125I]RTI 82.
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Figure 28. Specificity of Immunoprecipitation of [125I]D-147 Labeled Fragments.
[125I]D-147 labeled rat striatal membranes were subjected to trypsin proteolysis
and

immunoprecipitation

with

antibody

16

or

antibody

5.

During

the

immunoprecipitation procedure, samples were supplemented with no peptide, 50
pg/rnL peptide 16 or 50 pg/rriL peptide 5, as indicated (upper panel). Schematic
diagram of rDAT showing predicted structure and membrane topology (lower
panel). Transmembrane (TM) domains are shown as cylinders, the trypsin
cleavage site on EL2 (R218) is shown as a yellow circle, and antibody epitopes
are indicated by colored bold lines with numbers. Arrows indicate relationship of
autoradiograph fragments to domains in schematic DAT. Cleavage of [125;]D-147
labeled DATs at R218 generated a N-terminal 45 kDa fragment that originated
from TMs 1-3 (magenta), and a C-terminal 32 KDa fragment that generated at
TMs 4-12 (blue).
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The present results indicate that the [125I]D-147 labeled 45 kDa fragment
obtained by peptide mapping originates from rDAT N-terminal to the EL2 residue
R218 and includes TMs 1-3, and the 32 kDa precipitated tryptic fragment is
derived from rDAT C-terminal to R218 and contains TMs 4-12 (Figure 28). The
presence of smaller -1 6 kDa labeled fragments that precipitate with both
antibody 16 and antibody 5 indicate that [125I]D-147 becomes incorporated into
both the TMs 1-2 region and the TMs 4-7 region. Thus, in contrast to the closely
related GBR-like ligand [125I]DEEP that incorporates almost exclusively into TMs
1-2, the differential positioning of the reactive iodo-azido group in [125I]D-147
generates a distinct incorporation pattern.
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CHAPTER IV
DISCUSSION
The plasma membrane is an essential component of the cell and functions
to surround it, determining its boundaries and separating it from the outside
environment [128]. The membrane consists of prote n molecules embedded in a
thin double layer of lipids. The protein composition varies in different cell types
according to their specific functional properties and provides them with exclusive
characteristics. Transmembrane proteins, including DAT, traverse the lipid
bilayer and contain portions of their structure on both sides of the membrane.
They possess amphipathic characteristics, with their hydrophobic regions
interacting with the lipids and their hydrophilic domains in contact with water at
both sides of the membrane. Due to their amphipathic structure, common
methods to study protein tertiary structure such as x-ray crystallography and
nuclear magnetic resonance (NMR), are extremely complex to execute and
analyze for these transmembrane proteins. Thus, more indirect biochemical
techniques have been applied in order to describe DAT’s structural conformation,
molecular mechanisms, and active sites.
Photoaffinity labeling was initially utilized to visualize dopamine transport
sites in mammalian tissue before DAT became cloned and characterized
[125,126], Additionally, the GBR analogue [125]DEEP and the cocaine analogue
[125]RTI 82 were demonstrated to label the same protein in rat striatal
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preparations, with identical pharmacological profiles [127]. After the cloning of
DATs in the early 1990s, photoaffinity labeling in combination with peptide
mapping and epitope-specific immunoprecipitation was used in order to localize
the binding sites for a variety of structurally diverse DAT inhibitors. [125I]DEEP
and [125I]RTI 82 were found to attach to TMs 1-2 and TMs 4-7 respectively,
suggesting the possibility of distinct incorporation sites for different classes of
uptake biockers [110,111]. Soon after, the incorporation site of the benztropine
analogue [125I]GA 2-34 was mapped to the TMs 1-2 region, and the GBR
analogue [125l]AD-96 was demonstrated to attach to both the TMs 1-2 and the
TMs 4-7 domains [112,113]. The fact that incorporation of numerous structurally
diverse photoaffinity labels occurs in the same domains suggests that these
uptake blockers bind to a common pocket on DAT, composed at least partially of
TMs 1-2 and 4-7, and further that they inhibit transport by a similar mechanism,
supporting the hypothesis of three-dimensional proximity between the regions
encompassing TMs 1-2 and TMs 4-7 in the tertiary structure of DAT.
TM1 is a Determinant for Cocaine Binding in DAT
In this study, using photoaffinity labeling in combination with enzymatic
and chemical proteolysis, epitope-specific immunoprecipitation, and site-directed
mutagenesis, the incorporation site on DAT for the novel cocaine analogue
[125I]MFZ 2-24 was localized to TM1, more specifically to a domain containing
residues 67 to 80. This represents the first time that the use of photolaboling has
allowed the positive identification of such a small number of residues as the
binding site for a cocaine analogue in DAT. The finding that irreversible
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incorporation of [125I]MFZ 2-24 occurs in TM1 strongly suggests that the
reversible binding site for cocaine is located within this domain, somewhere
between residues I67 and L80.
The DAT region encompassing TM1 has been extensively studied through
a variety of approaches due to its high degree of conservation among related
transporters, and has been implicated in substrate and inhibitor binding through
several

lines of evidence.

Studies using

DAT-NET chimeras suggested

interaction of TM1 with cocaine as demonstrated by lower cocaine affinity in
constructs whose junction points lie in or near this domain [93].
The chemical structure of DA and other DAT substrates, with the
phenethylamine group positively charged at physiological pH, have led the
search for charged, aromatic and polar residues as potential targets for
mutagenesis. TM1 in DAT harbors D79, the first amino acid shown to be
essential for DAT function. Substitution of this residue to alanine, glycine or
glutamic acid results in profound losses in DA and cocaine analogue affinities
[96]. It has been proposed that the carboxyl group of D79 is essential for
interaction with the positively charged amine from DA, and possibly with the
tropane nitrogen in cocaine. Importantly, this residue is conserved within the
related monoamine transporters NET (D75) and SERT (D98), and similar effects
on substrate uptake have been observed upon amino acid substitution at these
positions [129], Mutation of rDAT F76, located one helical turn below D79, to
alanine results in extensive loss of affinity for CFT binding to DAT [97], The
analogous Y95 in SERT and F72 in NET exhibit reduced substrate and inhibitor
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binding affinities, highlighting the functional importance of this position throughout
the monoamine transporter family [130,131]. Conversely, mutation of W84 to
alanine in rDAT and leucine in hDAT leads to increased affinity for the cocaine
analogue CFT [98,132], Additionally, ionic dependence studies of the W84L
mutant in hDAT revealed that this mutation contributes to stabilizing the
transporter on an outward facing conformation, with increased affinity for cocaine
[98]. Substitution of D68 for asparagine in hDAT led to a significant loss in
cocaine analogue affinity, but an even greater loss in affinity for a GBR analogue,
implicating this residue in binding of different classes of inhibitors [133].
The findings from this study using photoaffinity labeling extend and
complement previous studies that implicate TM1 in cocaine binding, and further
provide a separate line of biochemical evidence that supports the involvement of
this domain in the active site of DAT.
Relationship with Bacterial Leucine Transporter (LeuTAa)
The leucine transporter from Aquifex aeolicus (LeuTAa) is the first member
of the

Na7CI'-dependent family

of transporters

to

be crystallized

with

exceptionally high resolution [69]. Although distantly related to DAT (only 20%
homology) the TMs show high degree of similarity, and a large amount of
biochemical evidence, including data from photoaffinity labeling studies, supports
the assumption that DAT adopts a similar three-dimensionai conformation. In
LeuTAathe binding site for leucine and Na+ is composed mainly of TMs 1, 6, 3
and 8. Interestingly, TMs 1 and 6 are not continuous helices but contain non
helical unwound regions that are in direct contact with both substrate and ions. In
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TM1 leucine binding occurs to both sides of the unwound regions at residues
corresponding to DAT A77, L80 and A81 whereas the Na^ ions are coordinated
by the carboxyl group of leucine, and LeuTAa A22, N27, G20 and V23,
corresponding to DAT residues A77, N82, G75, and V78 (Figure 29). All the
previously described DAT mutations involved in substrate and inhibitor binding
(D79, F76, W84 and D68) are located within the boundaries of this essential
region in TM1 and are highly conserved, highlighting their importance in the
functional aspects of DAT active mechanism. The presence of a glycine in the
unwound region of TM1 in LeuTAa (G24) and the analogous position of its
mammalian counterparts, except for the biogenic amine transporters that
possess an aspartate, may be explained by the structure of the cognate
substrates. An aspartate at this position may contribute a carboxyl group that
replaces the one present in amino acid substrates, and could function as a Na+
coordination site in addition to directly interact with the amine from the
substrates.
The findings from these stjdies indicate that the cocaine interaction with
DAT occurs at residues located within this extremely important and highly
conserved region, more specifica.ly at a 13-residue stretch located N-terminal to
the substrate contact point at L80. Although the site for irreversible incorporation
of the cocaine analogue [125I]MFZ 2-24 to DAT will not likely be identical to the
residues that directly interact with the cocaine pharmacophore, measurements of
the interatomic distances between the reactive phenyl-iodo azido group and the
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Figure 29. Amino Acid Sequence Alignment of hDAT and LeuT/^. The FASTA
formatted sequences from LeuTAa (NP_214423) and hDAT (Q01959) were
aligned using the T-Coffee Multiple Sequence Alignment Tool [134], and
manually adjusted according to Beuming et al [71]. Colored bars indicate TM
domains, with amino acids from LeuTAa highlighted in bold letters.
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hDAT
LeuTA a
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TM 5

hDAT
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LeuT A a
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ITO FI8JV SII.IRGISKGIERFAK IAM PTLFILAV Fr.V IRVFLLETPN GTAA D GLN FLW TPD FE

TM 6
hDAT

TM 7

304 RLCEASVW IDA ATQ V CFSLGV GFGV LIA FSSYNKFTN NCYRDA IV TTSIN SLTSFSSGFW FS

LeuTA a 23 7

KLKDFGVW IAAVGQ IFFTLSLGFGAIITYASYVRKDQ DIVLSGLTAATLNEKAEVILGGSISI

TM 8
hDAT

3 6 7 FLGYMA--QKHSVP1GDVAKDGPGLIFIIYPEAIATLPLSSAW AW FF1M LLTLGIDSAM GGM

L eu T A a

301) PAAVAF FGVANAVA1AKAG- -A FN LG F1T LP A 1 FSQ TAGGTFLGFLW FFLLFFA GLTSSIAIM

TM 9
hDAT

TM 10

4 2 8 ESV ITG L1D EFQ LI.H R H R ELFTLFIV LA TFLLSLFC V TN G G 1 YVFTLLDHFAAGTS1LFGVL1

L e u T A a 3 6 1 Q PM IAFLEOELKL---- SRKHAVXWTAAIVFFSAHLVMFL--NKSLDEMDFWAGTIGVVFFGLT

TM 11

mmmm
hDAT

fmm mmm&mm mam fm

4 9 1 EAIGVAWFYGVGQFSDDI QQMTGQRPSLYWRLCWKLVSPCFLLFWWS IVTFRPPH YGAYIF

L e u T A a 4 1 9 BLZIFFW IFGADKAW EEINRGGI IK V P R i YYYVMRYITPAFLAVLLWWARJEYIPKIMEETH-

TM 12
554

PDWANALGWVIATSSMAMVPIYAAYKFCSLPGSFREKLAYA1APEKDRELVDRGEVRQFTLRH

LeuTA a 481

- -WTWITRFYIIGLFLFLTFLVFLAERRRNHE3A----------- -------- --- ----- -

hDAT

hDAT
L eu T A a

6 1 7 WLKV
------
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essential determinants of cocaine binding will allow more precise identification of
potential crucial contact points in DAT (Figure 30).
The novel structure provided by the crystallization of this bacterial
homologue represents a breakthrough in the structure/function studies of this
family of transporters, and despite being distantly related, the high homology
found within the TMs demonstrate its importance in serving as a template for
modeling the mammalian homologues, and complementing the large amount of
biochemical data that is consistent with this model. However, there are several
structural aspects that are not shared between LeuTAa and its eukaryotic
counterparts such as the size of the second extracellular loop that contains the
glycosylation and disulfide bonds, and the length of the N- and C-terminal tails
that participate in protein-protein interactions. Perhaps these modifications are
part of the evolutionary changes that led to their specialized functional properties,
ionic

dependences,

and

substrate

specificity.

Additionally,

LeuTAa

was

crystallized in a closed conformation, with leucine and ion sites occluded from the
aqueous environment at both sides of the membrane. The extracellular access
gate is formed by a small number of amino acids, but the cytoplasmic gate
consists of highly packed protein structure, with participating residues from TMs
1,3,6,8 and 10. This stationary structure does not provide information about the
mechanistic implications of substrate and ion movement across the membrane or
the inhibition of its function by cocaine and other compounds, leaving this area
open for future exploration.
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Figure 30. Structures of Cocaine and [125I]MFZ 2-24. A and B. Chemical
structures of [125I]MFZ 2-24 and cocaine. C. The interatomic distances in
[125I]MFZ 2-24 between the phenyl- odoazido arm and the tropane nitrogen or
the phenyl ring are indicated as arrows and obtained from energy minimization
calculations (see Materials and Methods).
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Photolabels with Identical Pharmacophore Exhibit Differential Incorporation
The irreversible attachment site for [125I]RTI 82 in DAT has recently been
mapped to TM6 [114], [125I]RTI 82 and [125I]MFZ 2-24 are identical cocaine
analogues that differ only in the position of the phenyl-iodoazido reactive group
(Figure 31). Since these compounds share the cocaine pharmacophore with the
crucial elements for cocaine binding, their reversible binding should be identical,
with a distinct irreversible incorporation site. The studies presented here
demonstrate that, in c itrast to [125]RTI 82, [125I]MFZ 2-24 attaches to TM1 in
hDAT. This is the first time that photolabels harboring identical pharmacophores
have been shown to exhibit distinct incorporation patterns. In addition, these
results demons* ate physical proximity of TMs 1 and 6 in the three-dimensional
arrangement of DAT and are consistent with DAT adopting a conformation
similar to that of LeuTAa (Figure 31B).
Furthermore, this study strongly supports the idea that multiple domains of
the DAT primary structure form a binding pocket and are involved in direct
interaction with cocaine. Although the exact amino acid to which [125I]MFZ 2-24
becomes attached is not yet identified, this study indicates that incorporation
occurs within only 13 amino acids in TM1, representing the shortest sequence
ever identified by photoaffinity labeling techniques.
Analysis of the Incorporation of a Novel Cocaine Analogue to DAT
The incorporation pattern of the novel cocaine analogue [125I]JHC 2-48,
the third member of this family of tropane-based DAT inhibitors (Figure 11), was
found to be different from that of [125I]MFZ 2-24 and [125I]RTI 82 in these
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Figure 31. Photolabels with identical Pharmacophore Attach to Distinct Sites in
DAT. A. Chemical structures of the cocaine analogues [125I]MFZ 2-24 and
[125I]RTI 82. They possess identical cocaine pharmacophore but the phenyiiodoazido reactive group is placed in a different position. Schematic diagram of
DAT indicating the incorporation site for [125I]MFZ 2-24 in TM1 between residues
I67 and L80 (magenta) and the attachment site for [125!]RTI 82 in TM6 between
residues 1291 and K336 [108] (blue). B. Schematic diagram of the proposed
binding pocket for DAT according to LeuTAa [69], showing TMs 1, 6, 3 and 8.
Cocaine is placed within this pocket, and the attachment sites for [125I]MFZ 2-24
(magenta) and [125I]RTI 82 (blue) are indicated.
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studies. More in-depth characterization, including site-directed mutagenesis, will
be necessary in order to localize its attachment domain. However, it is tempting
to speculate about the potential candidate incorporation domains for [125I]JHC 248. Based on the positions of the 13 methionine residues in hDAT and the
preliminary CNBr map of [125I]JHC 2-48 labeled hDAT, the potential domains for
incorporation of this compound are the regions encompassing TM8 and TM12.
Three methionines are located at positions 414, 424 and 427 in TM8, and two
other methionines are situated in TM12 at positions 569 and 572. If incorporation
of the ligand occurred in a residue located in between the methionines in these
domains, the resulting CNBr fragments would have masses of 1 kDa or less that
could not be resolved by the SDS-PAGE method, and are consistent with the
initial mapping results. In addition, TM8 residues S355 and I359 in LeuTAaare in
direct contact with the substrate leucine, whiie '.he homologous residues in hDAT
correspond to S422 and G426 in TM8 and are located between M414 and M427.
This implicates TM8 as a potential target for further investigation regarding the
attachment site of [125I]JHC 2-48. Furthermore, mutagenesis and chimeras
studies have demonstrated the participation of TM8 in ir jortant DAT functions
involving substrate and inhibitor binding [92, 93, 135]
[125I]D-147 Incorporation Provides Additional Evidence for Proximity of Domains
The findings from the present studies localize the irreversible incorporation
site on DAT for the novel GBR analogue [125I]D-147. This compound is
structurally identical to the previously characterized [125I]DEEP but the phenyliodoazido reactive group is placed in a different position with respect to the
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piperazine pharmacophore (Figure 24), and becomes incorporated into both
previously identified labeled regions TMs 1-2 and TMs 4-7. These results
complement previous findings where the related GBR-based compounds
[125l]AD-96 and [125I]GA 2-34, attach to one or both of these regions [112,113],
However, the exact domain to which any of these compounds becomes
incorporated remains to be explored.
The results of these studies suggest that the irreversible binding domains
in DAT are shared between structurally diverse uptake blocker analogues, and
further indicate that these compounds bind to a common binding pocket in the
transporter composed of various domains. The exact epitopes to which each
class of inhibitor attaches are not necessarily identical, but are contained within
the same domains, and further, their differential orientations within the binding
pocket lead to distinct incorporation patterns. These studies also demonstrate
that the DAT active site consists of multiple TM domains located distantly in the
primary structure but proximaily in the three-dimensional conformation of the
protein. The identification of TM1 as a cocaine binding domain complements the
finding that indicates TM6 is another component of the cocaine binding site. The
identical structures of [125I]MFZ 2-24 and [125I]RTI 82 allow their binding to DAT
with the same spatial orientation in the pocket, and the differential position of the
reactive group results in irreversible incorporation into discrete domains. This
strongly indicates that, although distant in the primary structure, TMs 1 and 6 are
in close three-dimensional proximity and are components, at least partially, of the
cocaine binding site in DAT. In addition, these studies provide biochemical
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evidence that supports the similarity of the three-dimensional arrangement
between DAT and LeuTAa, with TMs 1 and 6 as partial constituents of the active
site. Together these results indicate that the substrate and the uptake-blocker
binding sites may overlap and that these compounds may inhibit dopamine
transport by competing with the substrate for binding, or by locking DAT in an
open outwardly conformational state that prevents the necessary movements for
dopamine to be transported.
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APPENDIX A

Below is the nucleotide sequence of the 6xHis-hDAT insert. The 6xHistidine tag
is highlighted in cyan, the EcoRI restriction site is highlighted in grey, the coding
sequence is underlined, and TM1 is highlighted in bold letters.
5' - - 101

TGCTTACTGG CTTATCG AAA TTAATACGAC TCACTATAGG GAGACCCAAG
CTGGCTAGCG TTTA A A C TTA AGCTTACCAT GGGGGGTTCT H —
TATGGCTAGC ATGACTGGTG GACAGCAAAT GGGTCGGGAT
E coR I

201
301
401
501
601
701
801
901
1001
1101
1201
1301
1401
1501
1601
1701

CTGTACGACG
CTCAA CTCCC
TG TCTTCCG T
GAGGTGGAGC
CTCCA CCCTC
AGACCTGGGG

ATGACGATAA
AGTGTGCCCA
GGTGGCCCCG
TC A TC C TTG T
ACCAACCCGC
CAAGAAGATC

GGTACCTAAG
TGAGTAAGAG
GCTAAGGAGC
CAAGGAGCAG
GGCAGAGCCC
G A CTTTCTCC

GATCCAGTGT
CAAATGCTCC
CCAATGCCGT
AACGGAGTGC
CGTGGAGGCC

TGGCGGTGCC
TG CC A CTTTT
GCCGCTGGTG
GGTCATCCTC
CCTGGGCGCT
ATCCACTGCA
TGGTGACTCC
CACCTGCTGC
CATGGCATCG
GGTGCTGGTC
CCTCAGGGAA
ACTGCCCTGC
CAGAGCATAC
GGATTGACGC
GTGCTGATCG
GGACGCGATT
GCTTCGTCGT
CCCATCGGGG
CCCGGAAGCC
TC T TC A T C A T
GAGTCAGTGA
CCGTGAGCTC
TGTTCTGCGT
TTTGCAGCCG
AGTGGCCTGG
TGACCGGGCA

TTCCTG G TCC
CTACATGGAG
TCTGGAAGAT
A TC TC A CTG T
G CACTATCTC
ACAACTCCTG
AGTGGAGACA
CG AGTACTTT
ACGACCTGGG
ATCGTGCTGC
GGTGGTATGG
TCCTGCGTGG
CTGAGCGTTG
GGCCACCCAG
CCTTCTCCA G
G TCACCACCT
CTTCTCCTTC
ACGTGGCCAA
ATCGCCACGC
GCTGCTCACC
TCACCGGGCT
TTC A C G C TC T
CACCAACGGT
GCACGTCCAT
TTCTATGG TG
GCGGCCCAGC

CCTACCTG CT
CTGGCCCTCG
CTGCCCCATA
A'1’ "TCGGCTT
TTCTCCTCCT
GAACAGCCCC
GCTCGGGCCT
GAACGTGGCG
GCCTCCGCGG
TCTACTTCA G
ATCACAGCCA
GGTCACCCTC
ACTTCTACCG
GTGTGCTTCT
CTACAACAAG
CCATCAACTC
CTGGGGTACA
GGACGGGCCA
TC C CTCTG TC
CTGGGTATCG
CATCGATGAG
TCA TCG TCCT
GGCATCTACG
CCTCTTTGGA
TTGGGCAGTT
CTGTACTGGC

CTTCATG GTC
GCCAGTTCAA
CTGAAAGGTG
CTTCTACA AC
TCACCACGGA
AACTGCTCGG
CAACGACACT
TGCTGCACCT
TGGCAGCTCA
CCTCTGGAAG
CCATGCCATA
CCTGGAGCCA
GCTCTGCGAG
CCCTGGGCGT
TTCACCAACA
CCTGACGAGC
TGGCACAGAA
GGGCTGATCT
CTCAGCCTGG
ACAGCGCCAT
TTCCAGCTGC
GGCGACCTTC
TC TTC A C G C T
GTGCTGATCG
CAGCGACGAC
GGCTGTGCTG

GGTGGAATTC
GTGGGACTCA
GGGCCCGAAG
AGCTCACCAG
CAGGATCGGG

t g t c c g t c a t TGGCTTTGCT
GTGGACCTGG CCAACGTCTG GCGGTTCCCC TACCTGTGCT ACAAAAATGG
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ATTGCTGGGA
CAGGGAAGGG
TGGGCTTCAC
GTCATCATCG
GCTCCCCTGG
A TG CCCATCC
TTTGGGACCA
CCACCAGAGC
CAG CCTGCCT
GGCGTGAAGA
CGTGGTCCTC
TAGACGGCAT
G CG TCTG TTT
GGGGTTCGGG
ACTGCTACAG
TTC TC C T C C G
GCACAGTGTG
TC A TC A TC TA
GCCGTGGTCT
GGGTGGTATG
TGCACAGACA
C TC CTG TC C C
CCTGGACCAT
AAGCCATCGG
ATCCAGCAGA
GAAGCTGGTC

1801
1901
2001
2101

AGCCCCTGCT
ACCCCCCCAC
GCTGGGTCAT
TACAAGTTCT
CATTGCACCC
ACACGCTCCG
CAGGAAGTCA
A G T T T ----- 3 '

TTCTCCTGTT
TACGGAGCCT
CGCCACATCC
GCAGCCTGCC
GAGAAGGACC
CCACTGGCTC
TCCTGCAATG

CGTGGTCGTG
A CA TCTTC CC
TCCATGGCCA
TG GGTCCTTT
GTGAGCTGGT
AAGGTGTAGA
GGAGAGACAC

132

GTCAGCATTG
CGACTGGGCC
TGGTGCCCAT
CGAGAGAAAC
GGACAGAGGG
GGGAGCAGAG
GAACAAACCA

TGACCTTCAG
AACGCGCTGG
CTATGCGGCC
TGGCCTACGC
GAGGTGCGCC
ACGAAGACCC
AGGAAATCTA

APPENDIX B
Site-directed Mutagenesis Primers

The primers used for site-directed mutagenesis by the QuikChange® method are
shown below. The substituted codons are highlighted in magenta.

Name

Seauence

M116A
Sense
Antisense

5’-g g g a t g c c a c t t t t c t a c M
g a g c t g g c c c t c g g -35’-CCGAGGGCCAGCTCiilGTAGAAAAGTGGCATCCC-3'

M111L/M116L
Sense
5’GGTCATTGCTGGGHHCCACTTTTCTACHH g AGCTGGCCC-3’
Antisense
5’GGGCCAGCTCil|gGTAGAAAAGTGGll|gCCCAGCAATGACC-3'

L80M
Sense
Antisense

5’-GCTTTGCTGTGGAc 1H|GCCAACGTCTGGC-3’
5'-GCCAGACGTTGGC^B g TCCACAGCAAAGC-3'

!67M
Sense
Antisense

5’-CT GGGGCAAG A A G ^ H g ACTTTCTCCT GTCC-3’
5’-GGACAGGAGAAAGTC»lCTTCTTGCCCCAG-3'
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APPENDIX C
Shown is the nucleotide sequence of the 6xHis-hDAT insert with the primers
used for sequencing purposes in bold letters.

T7 promoter -1 (F)
TCACTATA GG GAGACCCAAG

TGCTTACTGG

CTTA TCG AA A

TTAATACGAC

CTGGCTAGCG

TTTAAACTTA

A G CTTA CCA T GG GGGGTTCT C A TC A TC A T C

ATCATCATGG

T A T G G C T A G C A T G A C T G G T G G A CA G CA A A T G G G T C G G G A T

C T G TA C G A C G A TG A C G A T A A

G G T A C C TA A G G A T C C A G T G T G G T G G A A T T C

CTCA A CTCCC AGTGTGCCCA

TGA GTA A GA G C A A A T G C T C C G T G G G A C TC A

TGTCTTCCGT
<-

G G T G G C C C C G G C TA A G G A G C C C A A T G C C G T GG GCCCG A A G

hDAT 4 (R)

GA GG TG GA GC T C A T C C T T G T
CTCCACCCTC ACCAACCCGt
AGACCTO .

G iG G A C C T G G

. i GAAGA T C

CAAGGAGCAG A A CG G A G TG C A G C T C A C C A G
u t^AGAGGCC C G TG G A G G CC CA G G A TC G G G
GACTTTCTCC

TGTCCGTCAT

TGGCTTTGCT

CCAACGTCTG GCGGTTCCCC

T A C C T G T G C T A CA A A A A TG G

CCTACCTGCT

CTTCA TG G TC ATTGCTGGGA

hDAT 2 (F) ->
T G G C G G TG C C T T C C T G G T C C

T G C C A C T T T T CTACATGGAG C TG G CCCTCG

G C C A G T TC A A

CAGGGAAGGG

TCTGGAAGAT CTGCCCCATA

CTG A A A G G TG

TGGGCTTCAC

GCCGCTGGTG

GGTCATCCTC A TCTCA CTG T ATGTCGGCTT
CCTGGGCGCT G CA CTA TCTC

TTCTCCTCCT

CTTCTACAAC GTCATCATCG
T C A CCA CG G A

GCTCCCCTGG

ATCCA CTG CA A C A A C TC C TG GAACAGCCCC AACTGCTCGG A TG C C C A T C C
T G G T G A C T C C A GTG G A G A CA

GCTCGGGCCT CAACGACACT

C A C C T G C T G C C G A G T A C T T T G A A CG TG G C G
<r

TTTGGGACCA

TG CTG CACCT CCACCAGAGC

hDAT 3 (R)

CATGGCATCG ACGACCTGGG GCCTCCGCGG
G G TG CTGG TC A TCG TG CTG C

TGGCAGCTCA

CAGCCTGCCT

T C T A C T T C A G C C T C T G G A A G G G CGTGA AG A
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CCTCA G G G A A

G G T G G T A T G G A TC A C A G C C A

CCATGCCATA

CGTGGTCCTC

A CTGCCCTGC

TCCTGCGTGG

CC TG G A G C C A

TAGACGGCAT

GGTCACCCTC

hDAT 3 (F)
CA G A G C A TA C C T G A G C G T T G A C T T C T A C C G GCTCTC-CGAG G C G T C T G T T T
G G A T TG A C G C G G C C A C C C A G G T G T G C T T C T

CCCTG GG CGT GGGGTTCGGG

GTGCTGATCG

TTC A C C A A C A A C T G C T A C A G

CCTTCTCCAG

C TA C A A C A A G

G G A C G C G A TT G T C A C C A C C T C C A T C A A C T C C C T G A C G A G C

TTCTCCTCCG

GCTTCGTCGT C T T C T C C T T C

CTG G G G TA C A

TGGCACAGAA

GCACAGTGTG

C C C A TC G G G G A C G T G G C C A A

GGACGGGCCA G G G C T G A T C T

TCATCATCTA

CCCGGAAGCC A TC G C C A C G C

T C CC TC TG TC CTCAGCCTGG GCCG TG GTCT

TCTTCATCAT

G C TG C TC A C C CTGGG TA TCG ACAG CGCCA T GGGTGGTATG

< r hDAT 2 (R)
G A G TCA G TG A T C A C C G G G C T C A T C G A T G A G

TTCCAGCTGC

CCGTGAGCTC

TCATCGTCCT

GGCGACCTTC C T C C T G T C C C

T G TTC TG C G T CACCAACGGT GG CATCTACG

TCTTCACG CT CCTGGACCAT

TTTGCA GCCG GCA CG TCCA T C C TC TTTG G A

GTGCTCATCG AAGCCATCGG

TTCA CGCTCT

T G CA CA G A CA

hDAT 4 (F) -»
AGTGGCCTGG

T T C T A T G G T G T T G G G C A G T T C A G C G A C G A C A TC C A G C A G A

TGACCGGG CA

GCGGCCCAGC CTGTA CTGGC GG CTGTGCTG GAAGCTGGTC

AGCCCCTGCT

TTCTCCTGTT

ACCCCCCCAC

TACGGAGCCT A C A TCTTCCC

CGTGGTCGTG GTCAGCATTG

TGACCTTCAG

CGACTGGGCC A ACGCGCTGG

GCTGGGTCAT CG CCA CA TCC

TC C A T G G C C A

TGGTGCCCAT CTATGCGG CC

TACAAGTTCT GCAGCCTGCC

T G G G T C C T T T CGAGAGAAAC T G G C C T A C G C

C A T T G C A C C C GA GA A GG ACC G T G A G C T G G T GGACAGAGGG G A G G T G C G C C
A CACG CTCCG

C C A C T G G C T C A AG GTGTAG A

CA GGAAGTCA

< r hDAT 1 (R)
T C C T G C A A T G GG AG AG A CAC GAACAAACCA A G G A A A T C T A

AGTTT

----- .

3'
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GGGAGCAGAG A C G A A G A C C C
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